⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now.

AL amyloidosis is urgent, not watch-and-wait. Abnormal light chains from plasma cells form amyloid fibrils that deposit in your heart, kidneys, nerves, and other organs. Every month of delay risks irreversible organ damage. Aim for diagnosis and treatment start within weeks.
Typing must be correct — your life depends on it. AL is different from ATTR, AA, and hereditary amyloidosis. Treatments that help one type can harm another. The gold standard is mass spectrometry on a tissue biopsy. Immunohistochemistry alone can mistype your amyloidosis, leading to fatal treatment errors.
Daratumumab + CyBorD (Dara-CyBorD) is the new frontline standard. The ANDROMEDA trial showed 76% five-year overall survival for Stage I–IIIa patients, with deep hematologic responses that protect organs. FDA granted accelerated approval in January 2021 and traditional (full) approval in November 2025.
Organ staging guides your prognosis and treatment intensity. The Mayo 2012 staging system uses cardiac troponin, NT-proBNP, and free light chain difference to assign stages I–IV. Higher stage means more urgent and intensive treatment.
Stem cell transplant is powerful but only for the right patients. Autologous stem cell transplant (ASCT) can produce deep, durable responses — but only about 20% of patients are eligible. Fitness assessment is critical.
Anti-fibril antibodies have had mixed results. Birtamimab (AFFIRM-AL) failed its Phase 3 trial and was discontinued. Anselamimab/CAEL-101 (CARES) missed its primary endpoint in the overall population but showed a clear survival benefit in the prespecified kappa (κ)-light-chain subgroup, and AstraZeneca is now pursuing approval in the EU and Japan for kappa AL — though neither antibody is available as a treatment yet. Promising new approaches also include venetoclax for t(11;14) patients, isatuximab, and early CAR-T cell therapy studies.
Your free light chain level is the most important number to track. Rapid reduction in the abnormal free light chain means the treatment is working and organ damage is slowing or stopping. Deep hematologic response (VGPR or CR) is the goal.
Get to an experienced team. AL amyloidosis is rare. University of Utah has a dedicated amyloidosis program. For complex cases, Stanford Amyloid Center and Mayo Clinic are the nearest specialized referral centers.

▼ Collapse

AL amyloidosis is increasingly understood through the lens of the underlying plasma cell genetics — not just the clone’s size, but its specific chromosomal characteristics. This information is shaping treatment decisions and will become more important as targeted therapies continue to develop.

The t(11;14) translocation: About 40% of AL amyloidosis patients have a chromosomal abnormality in their plasma cells called translocation t(11;14) — a swap of genetic material between chromosomes 11 and 14. This translocation places the BCL-2 gene under the control of a very active promoter, causing the plasma cells to overproduce BCL-2, a protein that prevents cell death (apoptosis). t(11;14) is detected by FISH (fluorescence in situ hybridization) from bone marrow biopsy material — this is why bone marrow biopsy with FISH is mandatory at diagnosis. t(11;14) has dual clinical significance:

Prognostic: t(11;14) AL tends to have slightly different clinical features — higher light chain secretion, more predominant lambda light chain, and historically was considered a risk factor for poorer transplant outcomes. Modern data with daratumumab-based therapy have changed this picture, and t(11;14) patients can achieve excellent outcomes with contemporary regimens.
Therapeutic: The venetoclax (Venclexta) revolution: venetoclax is a BCL-2 inhibitor approved for CLL and AML. In plasma cell disorders with t(11;14), the cells are exquisitely dependent on the BCL-2 pathway that venetoclax targets. Multiple case series and early trials have shown remarkable responses to venetoclax in t(11;14) myeloma and AL amyloidosis, including in heavily pretreated patients who have failed daratumumab. Venetoclax is not yet FDA-approved for AL amyloidosis specifically — it is currently used off-label or in clinical trials for relapsed AL — but its development is one of the most exciting precision medicine opportunities in this disease.

MRD (minimal residual disease) testing: Standard treatment response (CR, VGPR, PR) is measured by protein tests that detect the M-protein clone down to about 1 abnormal cell per 100 normal cells. MRD testing goes 10 to 1,000 times deeper, detecting residual disease when routine tests say "complete response." MRD negativity in AL amyloidosis is strongly associated with:

Deeper organ responses (the heart and kidneys recover more fully)
Longer progression-free survival
Potentially identifying patients who might safely discontinue maintenance therapy

MRD testing in AL is performed by next-generation flow cytometry (NGF) or next-generation sequencing (NGS) from bone marrow. Ask your team whether your center performs MRD testing at CR assessment — it is increasingly standard at major AL programs and in clinical trials.

What genetics cannot yet do for AL: Unlike myeloma, where multiple genetic subtypes (high-risk vs. standard-risk) clearly define treatment intensity and monitoring strategies, the genetic risk stratification in AL is still evolving. High-risk cytogenetics in myeloma (del(17p), t(4;14), t(14;16)) have a less clearly defined impact in AL because organ damage (especially cardiac stage) is the dominant prognostic driver. As targeted therapy options expand, genetics will become more central to treatment selection in AL — particularly for t(11;14) patients considering venetoclax-based approaches.

Understanding AL Amyloidosis

AL amyloidosis is a rare but serious condition caused by a small population of abnormal plasma cells in the bone marrow that produce a misfolded protein. That protein — a piece of an antibody called a light chain — does not fold the way it should. Instead of being safely recycled, it clumps into sticky, insoluble fibrils that travel through the bloodstream and deposit in the walls of organs throughout the body. Over months to years, these deposits physically displace normal tissue, causing the organs they invade to malfunction and, if untreated, fail.

The word “amyloidosis” describes any disease in which abnormal protein deposits — called amyloid — build up in organs or tissues. There are more than thirty distinct types of amyloidosis, each caused by a different protein. AL amyloidosis — the “AL” stands for amyloid light chain — is the most common type in the United States and the one discussed throughout this guide. It is not cancer, but it shares a root cause with a blood cancer called multiple myeloma: both involve an abnormal plasma cell clone. In AL amyloidosis, that clone is usually small and does not behave aggressively the way myeloma does. The damage is done not by the cells themselves, but by the protein they produce.

Why urgency matters. AL amyloidosis causes organ damage that is often silent until it is advanced. By the time breathlessness, swelling, or numbness appears, the heart or kidneys may have already sustained significant injury. Damage already done cannot always be reversed, even with excellent treatment. The most important action a newly diagnosed patient can take is to reach a specialist center quickly — treatment started before organ dysfunction becomes severe produces far better outcomes than treatment started after significant damage has accumulated. Days and weeks matter in this disease.

To understand AL amyloidosis, it helps to understand what plasma cells normally do. Plasma cells live in the bone marrow and are the immune system’s antibody factories. A healthy plasma cell produces a complete, correctly folded antibody made of two “heavy chain” protein strands and two “light chain” protein strands held together. These antibodies circulate, find foreign invaders, tag them for destruction, and are cleared away normally.

In AL amyloidosis, a small clone of plasma cells has acquired genetic errors — often a chromosomal rearrangement — that cause them to produce a light chain protein with an abnormal structure. This faulty light chain cannot fold correctly into a stable three-dimensional shape. Instead, when it encounters the right conditions outside the cell — a specific pH, temperature, or molecular partner — it misfolds and joins with other misfolded copies to form a long, twisted rope-like structure called an amyloid fibril.

These fibrils are extraordinarily stable. The body’s normal protein-clearance machinery cannot easily break them down. They accumulate progressively in the spaces between cells in organ tissue — in the walls of the heart muscle, in the filtering units of the kidney, along nerve fibers, in the walls of blood vessels supplying the gut. Each fibril deposit physically crowds out normal cells, disrupts the organ’s mechanical function, and triggers a local inflammatory response that causes additional damage.

The particular organs affected by AL amyloidosis depend partly on which type of light chain is produced (kappa or lambda) and partly on that patient’s individual biochemistry. Lambda light chains — especially those derived from a particular family called the VL6 subgroup — are especially prone to forming cardiac amyloid. Kappa light chains more often deposit in the kidneys. But the heart and kidneys are both commonly affected regardless of light chain type, and most patients have involvement of more than one organ.

Two biochemical properties of the specific light chain drive how fast damage accumulates: its inherent tendency to misfold (its “amyloidogenicity”) and its direct toxicity to heart muscle cells even before it forms fibrils. Research has established that soluble, pre-fibril forms of light chains are themselves toxic to cardiomyocytes — they trigger oxidative stress and cell death pathways independently of fibril formation. This means cardiac damage can begin before there is measurable amyloid on an echocardiogram or biopsy.

Once fibrils deposit, the organ damage has two components: the mechanical compression and architectural destruction caused by the deposits themselves, and ongoing toxicity from the circulating light chains continuing to be produced by the plasma cell clone. This is why treatment has two goals: eliminating the plasma cell clone to stop new light chain production, and supporting the affected organs while existing deposits are slowly (and incompletely) cleared.

Many patients first diagnosed with “amyloidosis” need to understand that there are completely different diseases that share the name. The treatment for each is entirely different, so correct typing is essential.

Feature	AL Amyloidosis	ATTR Amyloidosis	AA Amyloidosis
Causative protein	Immunoglobulin light chain (kappa or lambda)	Transthyretin (TTR), a liver protein	Serum amyloid A, an acute-phase protein
Root cause	Abnormal plasma cell clone (bone marrow)	Genetic mutation (hereditary) or age-related misfolding (wild-type)	Chronic inflammatory disease (RA, IBD, familial Mediterranean fever)
Typical organs	Heart, kidneys, nerves, liver, GI	Heart (primarily), peripheral nerves	Kidneys (primarily), liver, spleen
Who gets it	Usually adults 55–75; affects all races equally	Wild-type: elderly men 70+; Hereditary: depends on mutation (Val122Ile more common in Black Americans)	Anyone with untreated chronic inflammation
Treatment approach	Eliminate plasma cell clone (chemotherapy, transplant)	Stabilize or silence TTR protein (tafamidis, patisiran, vutrisiran, acoramidis)	Treat the underlying inflammatory disease
Urgency	Very high — cardiac damage accumulates rapidly	High for hereditary; slower for wild-type	Moderate — depends on inflammation control
How to distinguish	Requires mass spectrometry on biopsy tissue; monoclonal protein in blood or urine	TTR gene sequencing; DPD nuclear scan (cardiac ATTR); no monoclonal protein	SAA protein identification on biopsy; elevated inflammatory markers

This distinction is critical: ATTR cardiac amyloidosis is now treated with tafamidis (Vyndamax/Vyndaqel) or other TTR-stabilizing drugs — treatments that do absolutely nothing for AL amyloidosis. Treating AL amyloidosis as though it were ATTR, or vice versa, delays effective treatment and causes harm. This is why mass spectrometry typing of the biopsy tissue is not optional.

AL amyloidosis is rare. In the United States, approximately 4,500–5,000 new cases are diagnosed each year, corresponding to a prevalence of roughly 16.7 cases per million people per year. This makes it rarer than most cancers but more common than many well-known rare diseases. It is estimated that fewer than 100,000 Americans are living with the condition at any given time.

The median age at diagnosis is between 63 and 65 years. It is unusual under age 40 and rare under age 30. Men are diagnosed somewhat more often than women (roughly 60:40 ratio). AL amyloidosis affects all racial and ethnic groups, though the underlying plasma cell biology does not appear to vary substantially by race the way ATTR amyloidosis does.

Because the disease is rare and its early symptoms mimic common conditions — heart failure, nephrotic syndrome, carpal tunnel — the average delay from symptom onset to correct diagnosis has historically been 12 to 24 months or longer. This diagnostic delay is one of the most consequential problems in AL amyloidosis care. Patients often see cardiologists, nephrologists, rheumatologists, and neurologists before a hematologist makes the connection.

Approximately 12–15% of patients with AL amyloidosis simultaneously meet criteria for multiple myeloma. These patients require treatment strategies that address both diseases concurrently. The remaining 85–88% have what is sometimes called “smoldering” or “low-burden” plasma cell disease, where the bone marrow clone itself is the target of treatment rather than the primary cause of symptoms.

AL amyloidosis is often called “the great masquerader” because its symptoms arise from whichever organs happen to be most affected by fibril deposits. No two patients present identically.

Heart (most common and most dangerous)
Cardiac amyloidosis is the leading cause of death in AL amyloidosis and is present in approximately 70–80% of patients at diagnosis. Symptoms include shortness of breath with exertion, leg swelling, extreme fatigue, orthostatic hypotension, palpitations or abnormal heart rhythms (atrial fibrillation), and syncope in advanced disease.

Safety note — digoxin: Digoxin is specifically contraindicated in cardiac amyloidosis. Amyloid fibrils bind digoxin abnormally, concentrating it in the heart muscle and causing toxicity at doses that would be safe in a normal heart. Any patient with AL amyloidosis who is told to take digoxin should immediately discuss this with a specialist.

Kidneys
Renal involvement is present in roughly 65–70% of patients. Amyloid deposits in glomeruli cause foamy urine (proteinuria), leg and ankle swelling, nephrotic syndrome, and gradual decline in kidney function.

Peripheral and autonomic nerves
Occurs in roughly 15–20% of patients. Symptoms include burning or shooting pain in the feet, numbness progressing up the legs, postural lightheadedness, diarrhea alternating with constipation, and erectile dysfunction.

Gastrointestinal tract
Early satiety after only a few bites, significant unintentional weight loss (15–30 lbs over months), nausea, vomiting, bloating, diarrhea, and occasionally GI bleeding.

Liver
Present in approximately 25% of patients. Enlarged liver (hepatomegaly) and elevated alkaline phosphatase on routine blood tests are the most common findings.

Distinctive physical signs

Macroglossia — enlargement of the tongue. Present in approximately 10–15% of AL patients and extremely rare in other amyloid types. Highly specific for AL amyloidosis.
Periorbital purpura — spontaneous bleeding under the skin around the eyes (“raccoon eyes”). Occurs when amyloid deposits in small blood vessels make them extremely fragile. Striking appearance; should immediately prompt investigation for AL amyloidosis when seen in a middle-aged adult.
Carpal tunnel syndrome — especially bilateral. AL amyloidosis is present in approximately 10–15% of patients presenting with bilateral carpal tunnel requiring surgery.
Shoulder pad sign — bilateral soft swelling of the shoulders from massive amyloid deposits in the shoulder joint bursa. When present, nearly diagnostic.

The serum free light chain assay (sFLC) measures kappa (κ) and lambda (λ) free light chains separately. In AL amyloidosis, the abnormal plasma cell clone produces large quantities of one type, distorting the kappa/lambda ratio. The three reported numbers are:

Kappa free light chain level (normal: approximately 3.3–19.4 mg/L)
Lambda free light chain level (normal: approximately 5.7–26.3 mg/L)
Kappa/lambda ratio (normal: 0.26–1.65)

The difference between the abnormal (“involved”) light chain level and the normal (“uninvolved”) light chain level is the dFLC. The dFLC is used in staging (threshold 180 mg/L in Mayo 2012 staging) and monitoring. During treatment, falling free light chain levels signal that the plasma cell clone is being suppressed. A VGPR is defined as a dFLC below 40 mg/L. A complete hematologic response (CR) means the abnormal light chain is undetectable on standard tests.

AL amyloidosis sits along a spectrum of plasma cell disorders. MGUS (Monoclonal Gammopathy of Undetermined Significance) is the starting point — a small clone producing a monoclonal protein without direct organ damage, affecting approximately 3–4% of adults over 50. At a rate of roughly 1% per year, MGUS can progress to multiple myeloma, AL amyloidosis, or Waldenström macroglobulinemia.

In most AL amyloidosis patients, the bone marrow contains fewer than 10–15% plasma cells — far fewer than the 60–90% seen in florid multiple myeloma — yet the disease can be rapidly fatal because of organ toxicity from the light chains produced.

An important genetic finding: approximately 45% of AL amyloidosis patients have the chromosomal rearrangement t(11;14), which causes overexpression of cyclin D1 and creates high BCL-2 dependence in the plasma cells. This is directly relevant to treatment: venetoclax, a BCL-2 inhibitor, is highly effective in AL amyloidosis patients with t(11;14), and this genomic test is now part of standard workup at specialist centers.

Before modern treatment, median survival from diagnosis was approximately 12 months, and for patients with advanced cardiac involvement, only 3–6 months. With modern treatment — particularly daratumumab-based regimens — median overall survival now exceeds 5 years for many patients, and select patients with Stage I or II disease who achieve a complete hematologic response live a decade or longer with excellent quality of life.

The ANDROMEDA trial reported 76% 5-year overall survival in Stage I–IIIa patients when treatment began before end-stage cardiac failure. In Stage IIIb (the most advanced cardiac stage), outcomes remain substantially worse despite effective hematologic treatment.

This asymmetry — excellent outcomes if caught early, poor outcomes if caught late — is why diagnostic delay is the disease’s most dangerous enemy, and why any patient in whom AL amyloidosis is suspected should be evaluated urgently.

For caregivers. AL amyloidosis is an invisible illness that looks normal from the outside while silently damaging multiple organs. Fatigue in this disease is not laziness or depression; it is the direct result of cardiac and nutritional compromise. If your person needs to sit and rest frequently, gains or loses significant fluid weight week to week, or describes burning feet or lightheadedness on standing — these are real, measurable physiological events. Appointment fatigue is also real: newly diagnosed patients often face several appointments per week at multiple specialty departments. Your role in coordinating logistics, tracking medication timing, and advocating for timely specialist referrals is genuinely medical work.

Diuretics (loop diuretics such as furosemide or torsemide) are the mainstay of fluid management and can significantly relieve breathlessness and leg swelling.

Beta-blockers must be used very carefully in cardiac amyloidosis. The low heart rate caused by beta-blockers can dramatically reduce cardiac output in the thick, stiff amyloid-infiltrated heart.

Digoxin — specifically contraindicated. Amyloid fibrils bind digoxin, concentrating it in the heart and creating toxicity risk.

ACE inhibitors and ARBs are often poorly tolerated because they lower blood pressure in a patient population that already tends to have low blood pressure and orthostatic hypotension.

Anticoagulation is frequently required because atrial fibrillation and atrial flutter are common, and AL amyloidosis patients with atrial fibrillation are at high risk for thromboembolism.

Implantable defibrillators (ICDs): Whether to place an ICD is a nuanced, individualized discussion best made at a specialist center with joint input from cardiologists and hematologists experienced in amyloidosis.

Amyloidosis Research Consortium (ARC) — arci.org — the leading US patient advocacy and research organization for amyloidosis. Patient registry and searchable directory of amyloidosis specialists.

Amyloidosis Foundation — amyloidosis.org — patient support, medical advisory board, and helpline at 1-877-426-9524 (toll free).

Financial assistance for daratumumab (Darzalex Faspro): Janssen CarePath (janssencarepath.com). Phone: 1-877-CarePath (1-877-227-3728).

Leukemia & Lymphoma Society (LLS) Co-Pay Assistance: 1-877-557-2672.

Patient Advocate Foundation — patientadvocate.org — case management and financial aid navigation.

How do you know this is AL amyloidosis and not ATTR or AA? Was mass spectrometry performed on my biopsy?
Which organ systems are affected in my case, and which is most urgently compromised?
What are my free light chain levels, and which type — kappa or lambda — is involved?
Do I have the t(11;14) chromosomal translocation, and if so, does that change my treatment plan?
What is my Mayo 2012 stage, and what does that mean for my prognosis and treatment urgency?
Should I be seen at a specialized amyloidosis center, or is this institution experienced in treating AL amyloidosis?
Is digoxin, beta-blocker, or ACE inhibitor on my current medication list, and should it be discontinued?
How quickly will treatment start? What happens to my organs while we wait?
Is my plasma cell clone large enough to meet criteria for multiple myeloma?
Are there clinical trials available at this stage of my disease?

AL amyloidosis is caused by a small population of abnormal plasma cells in the bone marrow that produce misfolded immunoglobulin light chains. Unlike myeloma, where the plasma cell count is high (typically >10%), AL amyloidosis is usually caused by a low-level plasma cell clone (often just 5–15% of marrow cells) that nevertheless produces toxic proteins in quantities large enough to damage organs over years.

The misfolding problem: Normally, light chains fold into their correct 3D structure, perform their immune function, and are cleared from the body. In AL amyloidosis, a single clone produces a structurally abnormal light chain variant (unique to each patient) that misfolds and aggregates into insoluble fibril deposits instead of being cleared. These fibrils have a characteristic beta-pleated sheet structure that resists enzymatic breakdown. They accumulate in the extracellular matrix of organs and progressively disrupt normal tissue architecture.

Organs most commonly affected:

Heart (65–75% of AL patients): Amyloid fibrils infiltrate the heart muscle (myocardium), making the walls stiff. The heart can still squeeze (systolic function preserved early), but cannot relax properly between beats — this is called restrictive cardiomyopathy. Fluid backs up (first in the legs and abdomen, then the lungs). The stiffness also prevents the normal electrical conduction pattern, causing arrhythmias. Amyloid deposits in the atria increase stroke risk. The heart biomarker NT-proBNP reflects the degree of cardiac amyloid stress; most staging systems use it to predict prognosis.
Kidneys (50–70%): Amyloid deposits in the glomeruli (the filtering units) disrupt the barrier that normally keeps protein inside the body. The result is nephrotic-range proteinuria — sometimes >10 grams per day of protein in the urine. The kidneys gradually lose their ability to filter waste, leading to progressive CKD and potentially dialysis requirement if untreated. Unlike many kidney diseases, early AL nephropathy may show preserved eGFR despite massive proteinuria.
Liver (25%): Amyloid in the liver causes hepatomegaly (liver enlargement), elevated alkaline phosphatase, and sometimes ascites. Severe AL liver disease can cause cholestasis and coagulopathy.
Peripheral and autonomic nerves (20%): Neuropathy from AL causes pain, numbness, and tingling in the hands and feet (peripheral), and/or lightheadedness on standing, diarrhea/constipation alternating, swallowing difficulties, and sexual dysfunction (autonomic). Autonomic neuropathy in AL can be life-threatening due to severe orthostatic hypotension.
Soft tissue and GI tract: The classic “raccoon eyes” (periorbital purpura), macroglossia (enlarged tongue affecting speech and swallowing), jaw claudication, carpal tunnel syndrome, and shoulder pad sign all reflect soft tissue amyloid deposits.

Why AL progression is rapid without treatment: The misfolded light chains are directly cardiotoxic even before they aggregate into fibrils — they activate inflammatory pathways that damage heart cells. Amyloid fibrils also cause direct mechanical dysfunction. The combination of toxic soluble light chains AND structural fibril deposits explains why even partial suppression of the plasma cell clone (reducing light chain production) produces rapid improvement in organ function — a distinctive feature of AL compared to other organ diseases.

Diagnosis of AL Amyloidosis

Diagnosing AL amyloidosis correctly is one of the most technically demanding tasks in hematology. The disease mimics many common conditions, requires specialized tissue analysis, and must be distinguished precisely from other forms of amyloidosis before treatment can begin. An incorrect diagnosis — or an incomplete one — can result in the wrong treatment, with potentially fatal consequences.

The single most important diagnostic principle. Typing the amyloid — identifying which protein it is made of — is not optional. IHC (immunohistochemistry) alone is unreliable, with error rates of 10–20% or higher. The current gold standard is laser capture microdissection followed by mass spectrometry (LMD/MS) on Congo red-positive biopsy tissue. If your center does not offer mass spectrometry typing, tissue can be sent to a reference laboratory such as the Mayo Clinic Amyloidosis Laboratory, which processes samples from across the country.

Tests to identify the plasma cell clone:

Serum protein electrophoresis (SPEP) — identifies any abnormal “spike” indicating a monoclonal protein. Positive in about 50% of AL amyloidosis patients.
Serum immunofixation electrophoresis (SIFE) — identifies the specific type of M-protein. Positive in approximately 70% of AL patients.
Serum free light chain (sFLC) assay — the most sensitive blood test. Approximately 98% of AL amyloidosis patients have an abnormal sFLC assay.
24-hour urine UPEP and urine immunofixation (UIFE) — the urine can contain the abnormal light chain even when blood tests are normal.

Tests to measure organ involvement:

Troponin T (high-sensitivity preferred) — cardiac myocyte injury marker. Threshold in Mayo 2012 staging: ≥0.025 ng/mL (25 pg/mL).
NT-proBNP — cardiac stretch marker. Threshold in Mayo 2012 staging: ≥1800 pg/mL. Affected by kidney function — interpretation must account for renal impairment.
eGFR and 24-hour urine protein — quantifies kidney function and degree of protein loss.
Alkaline phosphatase — often markedly elevated (5–10x normal) when the liver is infiltrated by amyloid.
Coagulation studies — Factor X deficiency occurs in some AL amyloidosis patients because amyloid deposits in the spleen bind and sequester Factor X, causing unexpected bleeding.

Subcutaneous fat pad aspirate (abdominal fat biopsy)
Usually the first biopsy attempted — safe, minimally invasive, outpatient. Sensitivity approximately 75–85% in AL amyloidosis at experienced centers.

Bone marrow biopsy
Performed in every patient with suspected AL amyloidosis regardless of fat pad result, for two reasons: can show amyloid deposits (positive in ~50–60% of AL cases); and more importantly, quantifies the plasma cell clone and provides tissue for FISH cytogenetics to detect t(11;14).

Organ biopsy: kidney
Provides the highest sensitivity for renal amyloidosis (~95–100% when kidneys are clinically involved). Also provides tissue for mass spectrometry typing.

Organ biopsy: heart
Nearly 100% sensitivity when cardiac amyloidosis is present. Performed when other biopsy sites are negative and cardiac amyloidosis is the dominant presentation. Essential for distinguishing AL from ATTR cardiac amyloidosis.

The general diagnostic rule: Fat pad aspirate + bone marrow biopsy identifies the diagnosis in approximately 80–85% of AL amyloidosis patients. The remaining 15–20% require direct organ biopsy. A negative fat pad aspirate alone does not rule out AL amyloidosis if clinical suspicion remains high.

Congo red is a synthetic dye that binds specifically to amyloid fibrils. Under standard light microscopy it gives amyloid a salmon-pink color. Under polarized light, Congo red-stained amyloid produces vivid apple-green birefringence — pathognomonic for amyloid and present in no other human tissue element.

A positive Congo red stain confirms amyloid is present. It does not identify the type. Typing requires additional analysis — specifically mass spectrometry.

Why IHC is not sufficient for typing: Light chain IHC antibodies often fail to stain reliably because amyloid fibrils alter the antigenic epitopes. Non-specific background staining can produce false-positive results. TTR deposits can co-exist with a monoclonal protein in elderly patients, creating a “double positive” situation that only mass spectrometry can resolve.

Mass spectrometry (LMD/MS) is the gold standard. Congo red-positive areas are precisely cut from the tissue slide using a laser, then analyzed by mass spectrometry, which identifies the specific proteins by their molecular weights with near-perfect accuracy. Any positive Congo red biopsy should undergo mass spectrometry typing before treatment decisions are finalized.

The Mayo 2012 Staging System uses three biomarkers, each assigned a point if it exceeds its threshold:

Biomarker	Threshold	What it measures	Score if above threshold
Troponin T (cTnT)	≥0.025 ng/mL	Cardiac myocyte injury	+1 point
NT-proBNP	≥1800 pg/mL	Cardiac wall stress	+1 point
dFLC	≥180 mg/L	Plasma cell clone burden	+1 point

Stage	Points	Definition	Median OS (pre-daratumumab era)
Stage I	0 points	All three biomarkers below threshold	~94 months (>7 years)
Stage II	1 point	One biomarker above threshold	~40 months
Stage IIIa	2 or 3 points AND NT-proBNP <8500 pg/mL	Multiple biomarkers elevated; not yet end-stage cardiac	~14 months
Stage IIIb	2 or 3 points AND NT-proBNP ≥8500 pg/mL	End-stage cardiac amyloidosis	~6 months

The ANDROMEDA trial demonstrated 76% 5-year overall survival in Stage I–IIIa patients with Dara-CyBorD — transforming the outlook dramatically from these historical figures. Stage IIIb remains the most challenging group.

A dedicated renal staging system uses eGFR and 24-hour urine protein to predict progression to dialysis:

Renal Stage	eGFR	24-hr Urine Protein	3-Year Dialysis Risk
Renal Stage I	≥50 mL/min	<5 g/day	~3%
Renal Stage II	Either criterion met	(one criterion met)	~20–30%
Renal Stage III	<50 mL/min	≥5 g/day	~60%

The European Modification of Mayo Staging (2015/2019) established equivalent thresholds for troponin I (used in many European centers instead of troponin T) and incorporated the NT-proBNP >8500 pg/mL threshold to define Stage IIIb.

Echocardiography classic findings: increased wall thickness (≥12 mm), granular sparkling appearance of myocardium, diastolic dysfunction, reduced longitudinal strain with apical sparing (sensitivity ~93%, specificity ~82% for cardiac amyloidosis), preserved or mildly reduced ejection fraction, biatrial enlargement, pericardial effusion.

Cardiac MRI provides tissue characterization: diffuse subendocardial late gadolinium enhancement (LGE) in a characteristic “zebra stripe” pattern; elevated native T1 values; extracellular volume fraction (ECV) >40–45% (normal <30%). ECV correlates with amyloid burden and has prognostic value.

DPD/PYP scan warning: DPD (3,3-diphosphono-1,2-propanodicarboxylic acid) and PYP (technetium-99m pyrophosphate) nuclear scans are designed to confirm ATTR cardiac amyloidosis, NOT AL amyloidosis. AL amyloidosis can produce a positive DPD/PYP scan in approximately 15–20% of cases. A positive DPD/PYP scan in a patient who also has a monoclonal protein requires biopsy and mass spectrometry typing to determine whether the patient has ATTR, AL, or both. Treating with tafamidis when the disease is actually AL would be catastrophic.

FISH (fluorescence in situ hybridization) detects chromosomal abnormalities in plasma cells from bone marrow biopsy. In AL amyloidosis, the most critical finding is:

t(11;14) — the most important finding in AL amyloidosis
Present in approximately 45% of patients. This translocation places the CCND1 gene next to the immunoglobulin heavy chain promoter, driving cyclin D1 overexpression. The result: plasma cells become highly dependent on BCL-2 for survival, making them specifically vulnerable to venetoclax (Venclexta), a BCL-2 inhibitor.

The venetoclax-combination trial (NCT04847453, venetoclax + ixazomib + dexamethasone) is evaluating venetoclax in t(11;14)-positive AL amyloidosis with preliminary data showing extremely deep hematologic responses. t(11;14) testing is standard at diagnosis at experienced centers.

Other FISH findings: del(17p)/TP53 deletion (~10%, high-risk), t(4;14), gain 1q21. Every patient should have FISH cytogenetics performed on bone marrow at diagnosis.

Clinical suspicion raised — unexplained heart failure with preserved EF + thick walls, nephrotic syndrome, bilateral carpal tunnel, macroglossia, periorbital purpura, peripheral neuropathy without clear cause, profound weight loss + fatigue
Initial blood and urine panel — SPEP, SIFE, sFLC, 24-hour urine UPEP + UIFE, CBC, CMP, troponin T, NT-proBNP, coagulation studies, 24-hour urine protein
Cardiac imaging — echocardiogram with speckle tracking longitudinal strain; cardiac MRI with gadolinium and T1 mapping if echo equivocal
Tissue biopsy for Congo red — subcutaneous fat pad aspirate first; bone marrow biopsy always; organ biopsy if both negative and suspicion remains high
Congo red staining — confirms amyloid (apple-green birefringence under polarized light)
Mass spectrometry typing (LMD/MS) — on Congo red-positive tissue; mandatory before treatment begins
FISH cytogenetics — on bone marrow; specifically t(11;14), del(17p), t(4;14), gain 1q21
Mayo 2012 staging — from troponin T, NT-proBNP, and dFLC
Renal staging — from eGFR and 24-hour urine protein
ASCT eligibility assessment — approximately 20% of newly diagnosed patients qualify
Multidisciplinary team conference — hematology/oncology, cardiology, nephrology review together
Second opinion — at a dedicated amyloidosis center, appropriate for all newly diagnosed patients

On seeking a second opinion. AL amyloidosis is rare enough that even experienced hematologists may see only a handful of cases per year outside of major centers. The Stanford Amyloidosis Program (Dr. Ronald Witteles, 650-723-6649), BU Amyloidosis Center (Dr. John Berk, 617-638-4317), Mayo Clinic (Dr. Morie Gertz, 507-538-3270), and Columbia University (Dr. Suzanne Lentzsch) all accept referrals and tissue samples for second-opinion diagnosis and treatment planning — many can provide consultation without requiring the patient to travel immediately. In the UK, the UCL National Amyloidosis Centre (Prof. Philip Hawkins, +44 20 7794 0500) provides the equivalent service. In Utah, University of Utah Huntsman Cancer Institute (801-581-2121) is the primary referral point.

Was mass spectrometry performed to type my amyloid, or only immunohistochemistry? If only IHC, can the tissue be sent to a reference lab for LMD/MS?
What were my Congo red biopsy results, and from which site?
What are my exact Mayo 2012 staging biomarker values — troponin T, NT-proBNP, and dFLC — and what stage am I?
What are my renal staging values — eGFR and 24-hour urine protein?
Did my echocardiogram show the apical sparing pattern? Was cardiac MRI performed?
Was a DPD or PYP scan performed? If positive, did I also have a monoclonal protein?
Do I have the t(11;14) translocation on FISH testing?
What percentage of my bone marrow is plasma cells, and do I also meet criteria for myeloma?
Am I eligible for autologous stem cell transplant?
Should I get a second opinion at a dedicated amyloidosis center before starting treatment?

The heart is the most important organ to assess in AL amyloidosis because cardiac involvement determines prognosis more than any other factor. Several cardiac tests are used:

Echocardiogram (cardiac ultrasound): The hallmark finding is increased left ventricular wall thickness (≥12 mm in a non-hypertensive patient, without another explanation). Other characteristic findings:

Granular sparkling texture of the myocardium — a pattern historically considered pathognomonic for cardiac amyloidosis, though it is less specific than once believed
Preserved ejection fraction (LVEF often ≥50%) despite severe symptoms — this is the restrictive pattern. The heart squeezes but cannot relax
Reduced global longitudinal strain (GLS) with relative apical sparing — a modern finding (visible on strain imaging) where the base and mid-walls contract less than the apex, reflecting the pattern of amyloid deposition. This is highly specific for cardiac amyloidosis vs. other causes of wall thickening
Diastolic dysfunction (E/e’ ratio elevated, shortened deceleration time)
Bi-atrial enlargement; small pericardial effusion
Thickened valve leaflets and interatrial septum

Cardiac MRI (CMR): Provides the most detailed characterization of amyloid in the heart. Late gadolinium enhancement (LGE) — diffuse subendocardial or transmural enhancement — is characteristic. T1 mapping shows elevated myocardial T1 values. CMR can quantify amyloid burden better than echo and is useful for monitoring response to treatment.

Cardiac biomarkers: Troponin (cTnT or cTnI) and NT-proBNP are essential for staging. They are elevated in proportion to cardiac amyloid burden and are used in the Mayo Clinic 2012 staging and newer staging systems (e.g., European Consensus 2021 staging incorporating FLC). Higher troponin and NT-proBNP correspond to worse prognosis. These biomarkers fall within weeks of starting effective treatment — one of the earliest signals that therapy is working.

Cardiac staging systems: The Mayo 2012 system divides AL patients into Stages I–IV based on: NT-proBNP <1800 vs ≥1800 pg/mL; troponin T <0.025 vs ≥0.025 ng/mL; and dFLC (involved minus uninvolved FLC) <180 vs ≥180 mg/L. Stage I: no abnormal criteria; best prognosis. Stage IV (all three abnormal): median survival historically <6 months without treatment. With modern daratumumab-based therapy, Stage IV outcomes have improved substantially but remain the most challenging group.

What to ask your cardiology team:

What is my cardiac staging? What does that mean for my treatment options?
Do I need a cardiac MRI, or is echo sufficient to guide decisions?
What is my NT-proBNP and troponin today, and when will we re-check them?
Should I see a heart failure specialist alongside my hematologist?

Treatment Options

Treatment of AL amyloidosis has two simultaneous goals: (1) eliminating the plasma cell clone producing the toxic misfolded light chains (hematologic response), and (2) supporting and protecting the organs already damaged by amyloid deposits through organ-directed care. The faster and deeper the hematologic response, the better the chance of organ recovery. Patients who achieve a complete response (CR) or very good partial response (VGPR) live substantially longer and have far greater rates of cardiac and renal organ recovery than those who achieve a partial response or less.

Treatment urgency. Unlike many cancers where a few weeks of planning are acceptable, AL amyloidosis—especially with cardiac involvement—requires starting treatment within days to weeks of diagnosis. The myocardium does not recover lost contractility once destroyed by amyloid infiltration. If your staging workup is not complete within 7 to 10 days of suspecting AL amyloidosis, ask your care team why not.

Daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) is the FDA-approved and NCCN-endorsed standard frontline regimen for most newly diagnosed AL amyloidosis patients not proceeding immediately to ASCT. It received FDA accelerated approval in January 2021 and full traditional approval as Darzalex Faspro (Janssen) in November 2025, based on the ANDROMEDA trial (NCT03201965).

How each drug works

Daratumumab (Darzalex Faspro): Human monoclonal antibody targeting CD38 on plasma cells. Kills plasma cells through CDC, ADCC, and direct apoptosis. Subcutaneous formulation (1,800 mg flat dose with hyaluronidase) takes 3-5 minutes vs 2-6 hours for IV daratumumab.
Cyclophosphamide: Alkylating agent. Given at 300 mg/m² orally on days 1, 8, 15 of each 28-day cycle.
Bortezomib (Velcade): Proteasome inhibitor. Given subcutaneously at 1.3 mg/m² on days 1, 8, 15, 22. Subcutaneous delivery significantly reduces peripheral neuropathy risk.
Dexamethasone: 40 mg orally weekly (20 mg for patients over 70 or with frailty).

ANDROMEDA trial key results (NCT03201965)

Hematologic CR: 59% vs 19% (p<0.001) — threefold improvement over CyBorD alone
VGPR or better: 79% vs 49%
Cardiac organ response: 43% vs 22% (p<0.001)
Renal organ response: 54% vs 27% (p<0.001)
5-year OS (Stage I-IIIa): 76% with Dara-CyBorD

A 2025 Mayo Clinic real-world analysis of 361 patients confirmed superiority in routine clinical practice.

Treatment schedule

Drug	Dose	Days	Duration
Daratumumab SC	1,800 mg flat dose	Weekly x8, then Q2W x8, then monthly	Until progression
Cyclophosphamide	300 mg/m² PO	Days 1, 8, 15	6 cycles then stops
Bortezomib	1.3 mg/m² SC	Days 1, 8, 15, 22	6 cycles then stops
Dexamethasone	40 mg PO (20 mg if age >70)	Weekly	6 cycles then stops

After 6 cycles, cyclophosphamide, bortezomib, and dexamethasone are discontinued. Daratumumab continues as monthly maintenance monotherapy until progression or intolerance.

Prophylaxis required

Antihistamine, antipyretic, and corticosteroid before each daratumumab injection
Montelukast for first 4 injections
Antiviral prophylaxis (acyclovir or valacyclovir) for full duration of daratumumab therapy
Pneumocystis prophylaxis (trimethoprim-sulfamethoxazole or alternative)

Key side effects

Peripheral neuropathy (bortezomib): Numbness, tingling, burning in hands and feet; up to 30%. Dose reduction or discontinuation if worsening.
Infections: Daratumumab impairs B-cell function for months. Vaccinations should be given at least 4 weeks before starting where possible.
Blood sugar elevation: Dexamethasone raises blood glucose; close monitoring for diabetic patients.
Blood typing interference: Daratumumab binds to CD38 on red blood cells causing positive Coombs tests. Inform blood bank before any procedures requiring crossmatch.

Financial assistance

Janssen CarePath: 1-844-553-2734 / janssencarepath.com/patient/darzalex
LLS co-pay assistance: 1-877-557-2672
Patient Advocate Foundation: 1-866-512-3861

ASCT remains one of the most powerful tools in AL amyloidosis for eligible patients, capable of producing deep, durable remissions. Only approximately 20% of newly diagnosed patients qualify due to organ damage already present at diagnosis.

ASCT eligibility (key thresholds)

Age: generally ≤70 years (physiologic fitness matters more than chronological age)
NT-proBNP: <5,000 pg/mL
Cardiac troponin T: <0.06 ng/mL
eGFR: ≥30 mL/min (dose-reduced melphalan for eGFR 30-50)
ECOG performance status: ≤2
LVEF: ≥45%

The ASCT process

Induction: 2-4 cycles of Dara-CyBorD or CyBorD to reduce light chain burden before transplant
Stem cell mobilization: G-CSF (filgrastim) for 4-5 days; plerixafor added for poor mobilizers; minimum 2×10⁶ CD34-positive cells/kg collected
Apheresis: stem cells collected and frozen over 1-2 days
High-dose conditioning: melphalan 200 mg/m² IV (dose-reduced for renal impairment)
Stem cell infusion (Day 0): thawed cells infused over 15-30 minutes
Engraftment: new blood cell production begins 10-14 days after infusion; close monitoring and transfusion/antibiotic support during nadir
Discharge: approximately 2-3 weeks post-infusion once counts recover

Outcomes

Treatment-related mortality (TRM) at experienced centers: approximately 1-2%
5-year overall survival after ASCT in eligible patients: approximately 80%
Hematologic CR rates: 40-55% without induction; up to 70-80% when ASCT follows Dara-CyBorD induction

Hematologic response criteria (IWG/ISA 2012)

Response	Definition	Significance
CR	Negative serum and urine immunofixation; FLC ratio normalized	Best possible; highest organ recovery and survival. Target for all patients.
VGPR	dFLC <40 mg/L	Strong response; organ recovery likely. Minimum acceptable target.
PR	dFLC reduction ≥50% from baseline	Meaningful but organ recovery less likely; consider intensification
Progression	dFLC increase ≥50% from nadir (if dFLC ≥100 mg/L); or new organ involvement	Treatment change required

Organ response criteria

Cardiac: NT-proBNP decrease ≥30% and ≥300 pg/mL from baseline; or NYHA class improvement ≥2 classes
Renal: Proteinuria decrease ≥30% without worsening eGFR (≥25% decline)
Liver: Alkaline phosphatase decrease ≥50%; or hepatomegaly decrease ≥2 cm by imaging

Organ response typically lags hematologic response by 6-12 months. Do not lose hope if organ function appears unchanged in the first few months after achieving CR.

Critical drug warnings in cardiac amyloidosis.

Digoxin: AVOID. Binds amyloid fibrils; causes life-threatening arrhythmias at standard doses.
Verapamil and diltiazem: ABSOLUTELY CONTRAINDICATED. Also bind amyloid fibrils; can cause severe hypotension, heart block, and cardiac arrest.
ACE inhibitors/ARBs: Generally avoided; the stiff amyloid heart is exquisitely sensitive to preload reduction.
Beta-blockers: Use with extreme caution only; can severely worsen hemodynamics.
NSAIDs: Worsen kidney function and increase fluid retention. Avoid entirely.

What IS used: Loop diuretics (furosemide, torsemide) for fluid management; anticoagulation for atrial fibrillation; sodium restriction (<2 g/day); fluid restriction (<1.5 L/day if significant heart failure); gentle activity.

Renal management: Low-sodium diet; diuretic therapy; nephrologist-guided ACE inhibitor use (only if hemodynamics tolerate); dialysis for end-stage renal disease.

Neurological management: Gabapentin (100-900 mg three times daily) or pregabalin (25-300 mg/day) for neuropathic pain; fludrocortisone + midodrine + compression stockings for orthostatic hypotension.

GI management: Soft diet for macroglossia; prokinetics for gastroparesis; octreotide for refractory secretory diarrhea; nutritional support for malabsorption.

Daily weight: Same time, same scale, same clothing every morning. Report gain >2 lbs/day or >5 lbs/week immediately.
Fluid tracking: Keep a log if team has set a daily limit. All liquids count.
Medication management: Maintain a current list; know which are forbidden (digoxin, verapamil, diltiazem); flag new prescriptions from any provider against this list.
Infection vigilance: Fever >100.4°F during treatment is a medical emergency — call immediately even at night.
When to call 911: Loss of consciousness; chest pain with sweating or shortness of breath; sudden severe shortness of breath; inability to wake the patient.
Caregiver self-care: Accept help. Use respite resources. Join Amyloidosis Support Groups (support.amyloidosissupport.com). Maintain your own healthcare.

Is Dara-CyBorD the recommended treatment for me? If not, why not?
Am I eligible for autologous stem cell transplant? If not now, could I become eligible after responding to treatment?
What is the goal of treatment — CR, VGPR, or stable disease control?
How often will free light chains be checked to monitor response?
What medications must I completely avoid because of cardiac amyloidosis? Can you give me a written list?
Do I need antiviral prophylaxis (acyclovir) while on daratumumab? For how long?
Who should I call if I develop a fever while on treatment? Is there an after-hours number?
Is there a clinical trial available — particularly if I have the t(11;14) translocation?
What financial assistance programs are available for my specific medications?

High-dose melphalan followed by autologous stem cell transplant (HDM-ASCT) is the most effective therapy available for AL amyloidosis in appropriately selected patients — achieving hematologic complete response (CR) in 40–50% and deep organ responses in many. However, only about 20–25% of newly diagnosed AL patients meet criteria for transplant due to the strict organ function requirements.

Transplant eligibility criteria (typical thresholds, from Boston University/Mayo/UCSF protocols):

Age ≤70 (some programs individualize up to 75)
Performance status: ECOG 0–2
Cardiac: ejection fraction ≥45%; BNP <400 pg/mL or NT-proBNP <5,000 pg/mL; no room air O2 requirement; no uncontrolled arrhythmia; no NYHA Class III/IV heart failure
Blood pressure: supine systolic ≥90 mmHg without vasopressors; orthostatic drop must be manageable
Renal: eGFR ≥30–40 mL/min (program-dependent; some proceed with dialysis)
No more than 2 organs involved (some centers allow 3 with preserved function)
Hepatic and coagulation: bilirubin <3, acceptable coagulation parameters

The transplant process: After induction chemotherapy (typically 4–6 cycles of bortezomib-based or daratumumab-based therapy), candidates undergo stem cell mobilization and collection as described below. High-dose melphalan (140–200 mg/m²) is given 2 days before stem cell infusion. The myeloablative conditioning destroys the abnormal plasma cell clone. Stem cells are re-infused and engraft within 10–14 days. Hospital stay is typically 3–4 weeks; full recovery takes 3–6 months. Transplant-related mortality (TRM) at specialized AL centers is 1–3% in properly selected patients.

Why not everyone qualifies: The high-dose melphalan conditioning places enormous stress on the heart and kidneys — the very organs that amyloid has damaged. Even in eligible patients, the cardiac compromise of AL means transplant in this disease is riskier than in myeloma; this is why AL transplant should be performed only at specialized centers with specific AL expertise (not general bone marrow transplant programs that do primarily myeloma).

Post-transplant monitoring: Hematologic response (dFLC, SPEP, SFLC) is checked every 3 months. Organ response lags 6–24 months behind hematologic response as amyloid deposits slowly remodel or are cleared. Complete hematologic response (CHR) + cardiac response is the highest-value outcome, associated with median survival >10 years in modern series. Consolidation therapy after transplant with daratumumab is being evaluated in trials.

Advanced Therapies & Clinical Trials

The AL amyloidosis treatment pipeline is more active than at any point in the disease's history. While only Dara-CyBorD is fully FDA approved for frontline treatment, venetoclax is highly effective for t(11;14) patients, and isatuximab, CAR-T cells, and bispecific antibodies are producing remarkable results in early trials.

Honest update on anti-fibril antibodies (2025–2026). Birtamimab (AFFIRM-AL, NCT04973137) failed its Phase 3 trial and was discontinued. Anselamimab/CAEL-101 (CARES, NCT04512235) missed its primary endpoint in the overall population but helped the prespecified kappa (κ)-light-chain subgroup, and AstraZeneca is now seeking regulatory approval in the EU and Japan for kappa AL. Neither antibody is approved or available as a standard treatment yet (as of June 2026).

Birtamimab (NEOD001) — AFFIRM-AL (NCT04973137)

Anti-amyloid monoclonal antibody designed to bind and clear misfolded light chain amyloid from organs. Phase 3 in Stage IIIb AL amyloidosis patients. Results in 2025: no statistically significant improvement in primary composite endpoint (all-cause mortality and cardiac hospitalization). Program discontinued by Prothena. Not available. Not enrolling.

Anselamimab (CAEL-101) — CARES (NCT04512235 / NCT04504825)

Anti-amyloid antibody (AstraZeneca, acquired from Caelum Biosciences). Two parallel Phase 3 trials (Mayo Stage IIIa and IIIb). Results reported 2025–2026: did not meet the primary endpoint in the overall study population, but a prespecified kappa (κ)-light-chain subgroup (72 patients) showed roughly 62% lower all-cause mortality and about 71% fewer cardiovascular hospitalizations versus placebo. AstraZeneca has regulatory submissions underway in the EU and Japan for kappa AL and holds Orphan Drug Designation (FDA, EC, Japan MHLW). Not yet approved or available anywhere as of June 2026.

The broader lesson still holds: suppressing the plasma cell clone (stopping new fibril production) is the backbone of treatment, and depth of hematologic response remains the primary target — anti-fibril antibodies are an add-on, not a replacement.

The t(11;14) translocation is present in approximately 45% of AL amyloidosis patients. It drives strong BCL-2 dependence in plasma cells, making them exquisitely sensitive to venetoclax (Venclexta, AbbVie), an oral BCL-2 inhibitor.

Clinical evidence — venetoclax-combination trial (NCT04847453, venetoclax + ixazomib + dexamethasone)

Overall hematologic response rate: approximately 65-80% in relapsed/refractory t(11;14) AL amyloidosis
VGPR or better: 50-65%
Time to response: approximately 1-2 months
Published Phase 1/2 data: 75% VGPR or better; real-world series: 88% hematologic response rate

FISH testing is mandatory before venetoclax. t(11;14)-negative patients do not benefit.

Key combinations under investigation

Daratumumab + venetoclax + dexamethasone (NCT06629818): Phase 2/3 for newly diagnosed t(11;14) AL amyloidosis
Venetoclax + dexamethasone: oral outpatient regimen for relapsed/refractory settings

Practical notes

Taken orally once daily with food; dose titrated over 3-5 weeks (ramp-up to minimize TLS risk)
Drug interactions: CYP3A4 substrate; avoid strong inhibitors (azole antifungals, certain antibiotics) and grapefruit
Not FDA approved specifically for AL amyloidosis — used off-label or within clinical trials

Ask about FISH testing at diagnosis. If FISH for t(11;14) has not been performed on your bone marrow biopsy, ask for it now. Results in 7-10 days; will not delay treatment. A positive result significantly changes your options.

Isatuximab (Sarclisa, Sanofi) is a CD38-targeting monoclonal antibody that binds a different epitope than daratumumab and directly induces plasma cell apoptosis, potentially offering activity after daratumumab progression.

SWOG S1702 results (NCT03499808) — Blood, November 2025

Overall hematologic response rate: 77.1%
VGPR or better: 57%
Median time to response: 1.1 months
Cardiac organ response: 57%; renal organ response: 50%
24-month PFS: 74%; 24-month OS: 85%

Isatuximab is FDA approved for myeloma but not AL amyloidosis. Use in AL amyloidosis is currently off-label or within clinical trials. A separate trial (NCT04754945) evaluates isatuximab + CyBorD for newly diagnosed high-risk AL amyloidosis including Stage IIIb patients.

Lenalidomide (Revlimid): Oral IMiD + dexamethasone (Len-Dex) for relapsed/refractory AL. Response rates approximately 50-60%. Critical cardiac caution: lenalidomide can cause significant fluid retention and cardiac toxicity (worsening heart failure, atrial fibrillation) in cardiac amyloidosis patients. Use at reduced doses with close monitoring; not recommended for advanced cardiac disease. Requires REMS program (Lenalidomide REMS, formerly RevAssist) and thromboprophylaxis. Renal dose adjustment required for eGFR <60 mL/min.

Pomalidomide (Pomalyst): Third-generation IMiD; active in lenalidomide-refractory patients. Pom-Dex or Pom-Cy-Dex; response rates approximately 40-55%. Same cardiac cautions as lenalidomide. Requires Pomalyst REMS.

Ixazomib (Ninlaro): The only oral proteasome inhibitor. Given on days 1, 8, 15 of a 28-day cycle. Response rates approximately 40-50%. Lower peripheral neuropathy risk than bortezomib — important for patients who developed bortezomib neuropathy in frontline therapy. Note: the Phase 3 TOURMALINE-AL1 trial did not meet its primary endpoint (hematologic response 53% vs 51% for physician’s choice), though time to organ deterioration/death favored ixazomib (HR 0.53); it remains a reasonable oral option in relapsed disease rather than a first-choice proven therapy.

CAR-T cells are the patient's own T lymphocytes, genetically engineered to target BCMA (B-cell maturation antigen) on plasma cells.

NXC-201 — NEXICART-2 trial

NXC-201 (Immix Biopharma), non-viral BCMA-targeting CAR-T, evaluated specifically for relapsed/refractory AL amyloidosis. Actively recruiting (NCT06097832; ~40 patients across 18 US sites — including Huntsman Cancer Institute in Salt Lake City, Utah). Preliminary data: overall response rates >80% with rapid, deep hematologic remissions in heavily pretreated patients.

Published results

Chinese study of 6 refractory AL amyloidosis patients: 100% hematologic CR and 100% renal CR at 640 days follow-up
Mayo Clinic retrospective of 9 patients receiving commercially available BCMA CAR-T (ciltacabtagene autoleucel or idecabtagene vicleucel, approved for myeloma): feasible; meaningful hematologic and organ responses

Key considerations

Requires lymphodepletion chemotherapy; cardiac amyloidosis patients at higher CRS-related hemodynamic risk
Manufacturing time 3-6 weeks; disease must be stable during this period
Available only within clinical trials or off-label at experienced centers

Bispecific antibodies simultaneously bind BCMA or GPRC5D on plasma cells and CD3 on T cells, triggering direct killing. Unlike CAR-T, they are "off-the-shelf" — no manufacturing delay.

Teclistamab (Tecvayli, Janssen): BCMA/CD3 bispecific, FDA approved for relapsed/refractory myeloma. In a series of 8 patients with concurrent myeloma and AL amyloidosis, all 8 achieved VGPR or better. An active trial (NCT07151690) investigates a BCMA/CD3 bispecific for newly diagnosed AL amyloidosis; primary completion December 2026.

Advantages: No manufacturing delay; generally outpatient after initial monitoring; may be active after CAR-T failure. Limitations: Require ongoing administration; infections from hypogammaglobulinemia; not approved for AL amyloidosis.

Do I have the t(11;14) translocation? If so, should venetoclax be part of my plan now or at relapse?
My disease has relapsed after Dara-CyBorD. What are my best options given current organ function?
Am I a candidate for a clinical trial? Which trials are currently enrolling at your center?
Should I be evaluated at Stanford, BU Amyloidosis Center, or Mayo Clinic for trial enrollment?
Is CAR-T cell therapy an option? Am I healthy enough for lymphodepletion chemotherapy?
What is the difference between daratumumab and isatuximab, and is isatuximab an option for my situation?
Are lenalidomide or pomalidomide safe for me given my cardiac involvement?
How do we define treatment failure, and when would you recommend changing therapies?
What happens if all treatment options are exhausted? Is palliative care a conversation we should begin?

One of the most frequently misunderstood aspects of AL amyloidosis treatment is the difference between hematologic response (how well the plasma cell clone is suppressed) and organ response (how much the damaged organs have recovered). Understanding this helps set realistic expectations for recovery timelines.

Hematologic response: Measured by dFLC (difference between involved and uninvolved free light chain), SPEP, SFLC, and bone marrow biopsy. Responses are graded as: Complete Response (CR) = SPEP/SIFE negative + normal FLC ratio; VGPR = dFLC <40 mg/L; PR = dFLC decrease ≥50%. Hematologic responses typically occur within the first 2–4 cycles of therapy — within 2–3 months of starting treatment. Earlier and deeper hematologic response predicts better organ outcomes.

Cardiac organ response criteria: NT-proBNP decrease ≥30% AND ≥300 pg/mL from baseline, OR a decrease in NYHA class. Cardiac response typically lags 3–12 months behind hematologic response. The amyloid fibrils themselves persist in the heart muscle after the toxic light chain production has stopped; the heart must mechanically remodel as fibrils are slowly cleared (a process that takes months to years). This is why patients may still have symptoms 6–12 months into a successful treatment despite excellent hematologic response.

Renal organ response criteria: Proteinuria decrease ≥30% from baseline (to <0.5 g/24h), without a significant decline in eGFR. Renal response also lags behind hematologic response, typically 6–18 months. Importantly, partial responses in proteinuria (30–50% reduction) are associated with significant slowing of CKD progression even if proteinuria does not fully normalize.

Setting realistic expectations: Complete hematologic response does not mean immediate organ recovery. It means the “ammunition supply” to the amyloid deposits has been cut off. Recovery then depends on the body’s ability to clear existing deposits — a process influenced by the type and extent of organ involvement, the patient’s own fibril clearance capacity, and time. Patients with early-stage disease (minimal amyloid deposition) recover faster and more completely. Patients with late-stage cardiac disease may achieve plateau improvement (cardiac function stabilizes) rather than full recovery — which is still a major clinical benefit and significantly extends survival.

class="content-section" data-stage="all">

Clinical Trials

Why Clinical Trials Matter. AL amyloidosis is rare (~16.7 cases per million per year in the US), which means every approved therapy we have today — including Dara-CyBorD — was proven in a clinical trial. Enrolling in a trial when eligible is often the fastest path to the most advanced care. Ask your amyloidosis specialist at every visit whether a trial is open for your current disease phase.

Landmark and Key Active Trials

NCT Number	NCT03201965
Official Name	ANDROMEDA: Daratumumab plus CyBorD vs CyBorD alone in newly diagnosed AL amyloidosis
Phase	Phase 3, randomized, open-label
Status	COMPLETED — led to FDA approval
FDA Approval	Accelerated approval January 2021; Traditional (full) approval November 2025
Key Result	Hematologic CR rate 59% (daratumumab arm) vs 19% (CyBorD alone); 5-year OS 76% for Mayo Stages I-IIIa on Dara-CyBorD
Key Reference	Kastritis E, et al. N Engl J Med 2021;385:46-58. PMID 34192431
Sponsor	Janssen Research & Development

NCT Number	NCT04847453
Official Name	Venetoclax, ixazomib and dexamethasone for relapsed/refractory AL amyloidosis (registry title; not formally named “EVIDENCE”)
Phase	Phase 1
Status	Active, not recruiting (closed to accrual; last updated May 2026)
Drug	Venetoclax (AbbVie) — BCL-2 inhibitor; not yet FDA-approved specifically for AL amyloidosis
Rationale	t(11;14) present in ~45% of AL amyloidosis patients renders plasma cells BCL-2 dependent; venetoclax exploits this dependency
Early Signal	Hematologic response rates 70-80%; 75%+ VGPR or better in published Phase 1/2 data
Sponsor	AbbVie

NCT Number	NCT03499808
Official Name	SWOG S1702: Isatuximab in Patients With Relapsed or Refractory AL Amyloidosis
Phase	Phase 2 (SWOG Cancer Research Network)
Key Results	77.1% overall response rate; 57% VGPR or better; 24-month OS 85% — published Blood November 2025
Status	Completed enrollment; results published
Drug	Isatuximab (Sanofi) — anti-CD38 antibody; FDA-approved for myeloma but not AL amyloidosis
Sponsor	SWOG / National Cancer Institute

Trial Name	NEXICART-2
Drug	NXC-201 (Immix Biopharma) — non-viral BCMA-targeting CAR-T cell product
Phase	Phase 2
Status	Actively recruiting (NCT06097832; ~40 patients, 18 US sites incl. Huntsman Cancer Institute, Salt Lake City)
Population	Relapsed/refractory AL amyloidosis
ASH 2024 Data	Overall response rates >80% with deep remissions in heavily pretreated patients

Phase 3 FAILED 2025. Birtamimab is NOT available outside of research. Do not seek this therapy.

NCT Number	NCT04973137
Drug	Birtamimab (NEOD001, Prothena) — anti-amyloid antibody targeting fibril deposits
Outcome	FAILED — did not meet primary endpoint (2025); program discontinued
Lesson	Clearing amyloid deposits after they form is much harder than suppressing the plasma cell clone. Hematologic response remains the primary treatment target.

Primary endpoint missed in the overall population (2025–2026), but the prespecified kappa (κ) subgroup benefited. Anselamimab is not yet approved or available anywhere (as of June 2026); EU and Japan regulatory reviews for kappa AL are underway.

NCT Number	NCT04512235
Drug	Anselamimab (CAEL-101, Caelum/AstraZeneca) — anti-amyloid antibody
Outcome	Missed primary endpoint overall (2025–2026); prespecified kappa subgroup (n=72): ~62% lower all-cause mortality, ~71% fewer CV hospitalizations. EU + Japan regulatory submissions underway for kappa AL.

How to Find AL Amyloidosis Trials

Step 1 — ClinicalTrials.gov: Search "AL amyloidosis" with status "Recruiting." Filter by country and phase.

Step 2 — Amyloidosis Research Consortium (ARC): arci.org maintains a patient-facing trial navigator with plain-language descriptions.

Step 3 — Ask your specialist: Ask specifically: "Am I eligible for any clinical trials?" and "Given my t(11;14) status, is the venetoclax trial (NCT04847453) open to me?"

Key eligibility factors: Mayo staging, organ involvement, prior lines of therapy, FISH cytogenetics (t(11;14)), creatinine clearance, performance status, and prior exposure to daratumumab or bortezomib.

Treatment access for AL amyloidosis varies significantly by country. Understanding approval status in your region helps you know what to ask your care team about, what may require special access pathways, and whether clinical trials may be your route to newer treatments.

United States (FDA): The US has the broadest approval portfolio for AL-relevant plasma cell treatments. Daratumumab (Darzalex) is FDA-approved for newly diagnosed myeloma indications and is widely used off-label for AL; the ANDROMEDA trial led to FDA approval of subcutaneous daratumumab for AL amyloidosis in January 2022, making Dara-VCd the first dedicated FDA approval for AL in nearly two decades. Bortezomib, lenalidomide, pomalidomide, carfilzomib, and isatuximab are all FDA-approved for plasma cell disorders. REMS programs apply to IMiDs (lenalidomide, pomalidomide) — required enrollment for dispensing. For refractory patients, CAR-T and bispecific antibodies approved for myeloma can be accessed through trials or specialist centers.

European Union (EMA): Daratumumab (Darzalex) received EMA approval for multiple myeloma indications; formal AL amyloidosis approval followed the FDA by approximately 12–18 months. The EMA issued a positive opinion on subcutaneous daratumumab + bortezomib + dexamethasone for AL amyloidosis in 2023. Access varies by member state — Germany and France have broader reimbursement, while some Eastern European countries may require individual patient authorization. The EMA requires Risk Minimization Measures (equivalent to REMS) for IMiDs, typically through the Thalidomide Celgene Pregnancy Prevention Program framework.

United Kingdom (MHRA/NICE): The UK National Amyloidosis Centre (UCL Royal Free Hospital, London) is one of the world’s two leading AL treatment centers and a key site for global AL trials. NICE has historically been restrictive in cost-effectiveness assessments for high-cost hematology drugs; some daratumumab combinations have required individual funding requests. Following Brexit, the MHRA issues independent UK approvals and has generally approved AL-relevant drugs within 6–12 months of FDA decisions. The NHS England Highly Specialised Technologies (HST) pathway applies to some rare disease treatments.

Japan (PMDA): Japan has a comprehensive AL amyloidosis care infrastructure with specialized centers at Shinshu University, Okayama University, and the National Cancer Center. The PMDA approved daratumumab for myeloma indications followed by the AL amyloidosis indication based on ANDROMEDA data. Japan’s drug approval timeline has accelerated under Sakigake (priority review) pathways, and most major plasma cell treatment approvals occur within 1–2 years of FDA decisions. PMDA conducts independent efficacy and safety reviews and may require Japanese-specific additional data.

Canada (Health Canada): Health Canada approves drugs on a similar timeline to FDA, typically 6–18 months later. Daratumumab is approved for myeloma indications and was reviewed for the AL indication through the Priority Review pathway. Provincial drug plans (OHIP, RAMQ, PharmaCare) control reimbursement and vary; specialized AL programs at Princess Margaret Hospital (Toronto) and Mayo Clinic-affiliated centers access drugs through provincial exceptional access programs where standard coverage is unavailable. Compassionate use programs are available from manufacturers for approved-indication drugs awaiting provincial formulary listing.

Australia (TGA/PBS): The Therapeutic Goods Administration follows FDA/EMA decisions closely. The Pharmaceutical Benefits Scheme (PBS) is the pricing and reimbursement gatekeeper; many newer myeloma-directed agents require Section 100 authority prescriptions and specific PBS criteria. The Peter MacCallum Cancer Centre (Melbourne) and Royal Prince Alfred (Sydney) are the primary AL centers. The RACP and ANZBMT publish local guidelines for AL management.

For patients in regions without dedicated AL approval: Formal AL amyloidosis approvals matter less than plasma cell disorder approvals in most countries — bortezomib, lenalidomide, and daratumumab are available throughout Europe, North America, Japan, and Australia in plasma cell indications, and amyloidosis specialists routinely use these on-label for myeloma with off-label reasoning when a dedicated AL approval is absent. What matters most is having a physician who is expert in AL and a center with experience in managing the cardiac and renal complications. International consultation (including telemedicine consultations with major amyloidosis centers) is widely available and is strongly encouraged for patients in regions without specialist AL expertise.

Caring for someone with AL amyloidosis is emotionally and physically demanding. The disease affects multiple organs simultaneously, treatment is intensive, and recovery timelines are measured in months to years — not days to weeks. This guide is for family members and designated caregivers who want to understand the disease and provide the most effective support.

Understanding what your loved one is experiencing:

Fatigue: Profound, treatment-related fatigue is the most common and disabling symptom throughout AL treatment. It is not laziness and it does not respond to pushing through it. Your role is to reduce energy demands on treatment days and for 1–2 days after each cycle, and to encourage rest without guilt. Fatigue often improves significantly after hematologic response is achieved.
Unpredictable good and bad days: On dexamethasone days (typically 1–2 days per week or cycle), your loved one may have energy and even euphoria — followed by a "steroid crash" 48–72 hours later with extreme fatigue, irritability, and low mood. This pattern is predictable but can be emotionally difficult for both patient and family. Planning activities for "up" days and rest for "down" days helps.
Fluid restriction frustration: Being restricted to 1.5–2 liters of fluid per day when thirsty (especially on steroid days) is genuinely difficult. Having low-calorie, low-sodium options available, and understanding that the restriction is medically critical, helps prevent caregiver conflict over food and drink choices. Small ice chips or sugar-free frozen treats can help satisfy the sense of thirst within the fluid limit.
Cognitive effects: Dexamethasone and chemotherapy can cause short-term memory difficulty, concentration problems ("chemo brain"), and sleep disruption. These are temporary in most patients. Being patient with repeat questions, keeping a shared notepad for important information, and not interpreting memory lapses as indifference supports the patient’s dignity and your relationship.
Anxiety and depression: Receiving a life-threatening diagnosis with rapid organ involvement is psychologically devastating. Depression and anxiety are extremely common in AL patients. Do not dismiss these as overreaction. Ask directly: "Are you feeling depressed? Are you afraid?" Normalize these feelings. Request a palliative care or social work consultation from the treatment team if not already offered — this is standard of care at AL-specialized centers.

Practical caregiver tasks:

Medication management: AL treatment regimens involve multiple drugs with complex schedules, and the consequences of missing a dose (especially antivirals and anticoagulation) can be severe. Maintaining a printed or digital medication schedule and accompanying the patient to appointments to hear instructions firsthand is critically important. Bring all bottles to every appointment.
Daily weight monitoring: If you are the primary caregiver, you may be the one who ensures the daily weight is taken, recorded, and acted upon. If weight increases 2–3 pounds in 24 hours, you may need to be the one who insists on calling the care team — even when the patient resists "bothering" them.
Infection vigilance: AL patients on chemotherapy are immunosuppressed. Fever >101°F is an emergency, not a wait-and-see situation. Know the after-hours number for the treatment center before the patient develops fever. Enforce handwashing with visitors; avoid bringing sick contacts into the home. Some AL centers recommend N95 masking in public during the first year of treatment.
Transportation: Chemotherapy infusions (daratumumab takes 3–5 hours), echocardiograms, blood draws, and specialist appointments may occur 2–4 times per month. Planning transportation in advance, including backup drivers, reduces stress on both patient and caregiver.
Advocating at appointments: Bring a written list of symptom changes, new concerns, and questions. Many AL patients underreport symptoms because they do not want to "worry" the team or cause treatment delays. You can say: "I noticed X at home — can you address that?" You are a member of the care team.

Caregiver self-care: Caregiver burnout is real and well-documented in amyloidosis caregiving. You cannot provide sustainable care if you are exhausted, resentful, or unwell. Practical strategies: designate one day per week when someone else handles primary caregiving; maintain one routine (exercise, hobby, social engagement) that is entirely yours; accept offered help specifically ("Yes — could you bring dinner on Tuesday?"); connect with other AL amyloidosis caregivers through the Amyloidosis Support Groups at amyloidosis.org. If you develop persistent low mood or feel unable to cope, speak to your own physician — caregiver depression affects the quality of care your loved one receives and deserves treatment.

International Access and Regulatory Status

AL amyloidosis is a rare, life-threatening disease recognized by regulatory agencies worldwide as a priority. Daratumumab plus CyBorD has received approvals across major health systems, though the pathway, reimbursement conditions, and access details differ.

Drug	DARZALEX FASPRO (daratumumab and hyaluronidase-fihj, Janssen) + CyBorD
Accelerated Approval	January 2021 — based on hematologic CR rate from ANDROMEDA
Full Approval	November 2025 — confirmed on OS and organ response data
Indication	Newly diagnosed AL amyloidosis in combination with bortezomib, cyclophosphamide, and dexamethasone
Insurance	Medicare Part B (infusion) and Part D (oral components); most commercial insurers cover with prior authorization; Janssen CarePath for co-pay support (1-800-652-6227)

NICE Guidance	Technology Appraisal TA959 (27 March 2024) — daratumumab with bortezomib, cyclophosphamide and dexamethasone recommended for NHS-funded use in newly diagnosed systemic AL amyloidosis (daratumumab stopped after 24 cycles or on progression)
EMA Full Approval	2025
National Specialist Center	UCL National Amyloidosis Centre — Royal Free Hospital, London
Lead Physician	Prof. Philip Hawkins
Phone	+44 20 7794 0500

EMA / EC Approval	European Commission marketing authorization June 2021 (CHMP positive opinion May 2021) for subcutaneous daratumumab + VCd in newly diagnosed systemic AL amyloidosis — the first approved treatment for this disease in Europe; applicable across all EU member states
Germany — Specialist	Prof. Stefan Schönland, Heidelberg University Hospital (Amyloidosis Centre)
Italy — Specialist	Prof. Giovanni Palladini, Amyloidosis Research and Treatment Center, University of Pavia / Fondazione IRCCS Policlinico San Matteo. Co-developer of Mayo 2012 staging and IWG criteria.

Canada (Health Canada)	Approved; provincial reimbursement varies. Princess Margaret Cancer Centre (Toronto), Dr. Suzanne Trudel, 416-946-4501; Ottawa Hospital BMT, 613-737-8899.
Japan (PMDA / MHLW)	Approved August 2021 (daratumumab SC for systemic AL amyloidosis — the first approved drug for this disease in Japan); NHI coverage. Major centers at National Cancer Center Tokyo, Keio University Hospital, Osaka University.
Australia (TGA)	TGA approved; PBS listing status — verify with treating center. Peter MacCallum Cancer Centre (Melbourne); Royal Prince Alfred (Sydney).

International Access Barriers — What Patients Should Know

Mass spectrometry-based amyloid typing (gold standard) is only available at specialized centers; IHC alone can misclassify amyloid subtype
Reimbursement approval often lags marketing authorization by 6-24 months depending on country and drug pricing negotiations
Patients in countries where Dara-CyBorD is approved but not yet reimbursed may access through manufacturer expanded access programs
Second opinions from international centers (UCL London, Pavia, Heidelberg) are routinely welcomed and can be arranged remotely with biopsy slides and laboratory records

AL amyloidosis treatment research has a difficult history: many approaches that showed theoretical promise or early signals have failed in properly controlled trials, often because the disease’s complexity was underestimated or because the organ damage at diagnosis was already too severe. Understanding what has not worked helps you evaluate new claims you may encounter and explains why the current evidence-based approach was slow to develop.

Colchicine: Used for decades in AA amyloidosis (a different type caused by inflammatory diseases) where it prevents the serum amyloid A protein that feeds AA deposits. Colchicine has no mechanism of action in AL amyloidosis — it does not affect immunoglobulin light chain production or clearance. It is not effective for AL and should not be used as an AL treatment. Occasionally prescribed in error by physicians unfamiliar with amyloid subtype distinctions.

High-dose dexamethasone as monotherapy: Before modern combination chemotherapy, high-dose dexamethasone alone was used as an AL treatment, exploiting its direct anti-plasma cell effect at high doses. Response rates were low (20–30% partial response), duration was short, and the cardiac and fluid-retention toxicities of high-dose steroids were very poorly tolerated in patients with cardiac amyloidosis. Monotherapy dexamethasone is obsolete for AL — all effective regimens combine it at lower doses with plasma cell-directed drugs.

Thalidomide-based regimens without bortezomib: Thalidomide was one of the first immunomodulatory drugs (IMiDs) evaluated in myeloma and AL. Early AL trials showed activity, but thalidomide’s severe side effect profile in AL — particularly the deep peripheral neuropathy (which compounds existing AL neuropathy) and the fluid retention and bradycardia (dangerous in cardiac AL) — led to poor tolerability at effective doses. Thalidomide-dexamethasone regimens were largely abandoned in AL in favor of bortezomib and lenalidomide-based combinations, and thalidomide is not recommended in AL guidelines.

Interferon-alpha maintenance: Used briefly in the 1990s–2000s as consolidation after transplant, by analogy with myeloma data at the time. The toxicity was substantial (fatigue, flu-like symptoms, worsening depression) and benefit was not demonstrated in AL-specific cohorts. Replaced entirely by modern post-transplant monitoring and, more recently, daratumumab consolidation trials.

Doxycycline as amyloid fibril disruptor: Laboratory studies showed that doxycycline could interfere with amyloid fibril stability and possibly accelerate clearance of existing deposits. Early small clinical series generated enthusiasm. However, the mechanism was never reliably translated to clinical benefit in prospective trials, and doxycycline is not recommended as an AL treatment in current guidelines. It remains an area of preclinical interest but has not moved forward as a standalone treatment. (Note: doxycycline is routinely used as antibiotic prophylaxis in immunocompromised patients with AL on chemotherapy for a different reason.)

Agents targeting the amyloid SAP component: CPHPC (miridesap) is a small molecule that depletes serum amyloid P component (SAP), a protein that coats and stabilizes all amyloid deposits including AL. Phase 1/2 data showed SAP depletion was feasible. A follow-on anti-SAP antibody (dezamizumab) was developed to trigger immune clearance of amyloid deposits after SAP depletion. While mechanistically elegant, early clinical results did not show the dramatic amyloid clearance anticipated in AL patients with cardiac involvement, and development in AL was deprioritized. Trials continue in ATTR amyloidosis where different dynamics may apply.

Summary of lessons learned: The history of AL treatment emphasizes several truths: (1) amyloid clearance is slow and difficult even with effective therapy; (2) cardiac safety must be evaluated specifically in AL, not extrapolated from myeloma data; (3) reducing the toxic light chain source (plasma cell clone suppression) is currently the most effective strategy; and (4) organ damage at diagnosis sets a ceiling on recovery that cannot be fully overcome even with perfect treatment. This is why early diagnosis and treatment initiation — before advanced organ damage accumulates — remains the most important modifiable factor in AL outcomes.

Therapies That Have Been Tried and Did Not Work

Understanding what has failed in AL amyloidosis is just as important as knowing what works. This section documents those results honestly — both to set accurate expectations and to explain why certain therapies a patient may read about online are not currently available or appropriate.

Not Yet Available: Birtamimab (AFFIRM-AL, failed and discontinued 2025) and anselamimab/CAEL-101 (CARES — missed overall endpoint but benefited the kappa subgroup; EU + Japan reviews underway for kappa AL) are not approved or available as standard treatments yet (as of June 2026). Patients with kappa-type AL can ask a specialist about anselamimab’s status.

What it was: Birtamimab (Prothena Corporation) was an anti-amyloid monoclonal antibody designed to directly bind and clear amyloid fibrils deposited in organs, particularly the heart. Early Phase 2/3 data had suggested a survival signal in Mayo Stage IV patients.

What happened: The Phase 3 AFFIRM-AL trial (NCT04973137) failed to meet its primary endpoint in 2025. No statistically significant improvement in survival or organ function compared with placebo. Prothena discontinued the program.

Why this matters: The AFFIRM-AL failure confirmed that directly clearing deposited amyloid from organs is extraordinarily difficult once fibrils have formed. Suppressing the plasma cell clone — stopping new fibril production — remains the most effective strategy.

Current status: NOT available. Not approved. Not in active development for AL amyloidosis.

What it was: Anselamimab (Caelum Biosciences, acquired by AstraZeneca) is an anti-amyloid antibody targeting AL amyloid fibrils in cardiac tissue, tested as an add-on to standard plasma-cell therapy.

What happened: The CARES Phase 3 program (NCT04512235/NCT04504825) did not meet its primary endpoint in the overall study population (Mayo stages IIIa+IIIb) when results were reported in 2025–2026. However, a prespecified subgroup with the kappa (κ) light-chain type — about 20% of AL patients — showed a large benefit: in the 72-patient kappa subgroup, all-cause mortality fell by roughly 62% (about 31% of anselamimab patients died vs about 58% on placebo) and cardiovascular hospitalizations dropped by about 71%. So the “failure” was only for the whole population — the kappa subgroup did benefit.

Current status: NOT yet approved or available anywhere (as of June 2026). Anselamimab is not discontinued — AstraZeneca has regulatory submissions underway in the EU and Japan for kappa AL amyloidosis, and it holds Orphan Drug Designation from the FDA, European Commission, and Japan’s MHLW. If you have kappa-type AL amyloidosis, ask your specialist whether this may become an option.

Thalidomide (first-generation IMiD) was tested in AL amyloidosis in the early 2000s and was poorly tolerated — excessive fluid retention, cardiac toxicity, and neuropathy. Abandoned.

Lenalidomide is used in relapsed/refractory AL amyloidosis at specialized centers but must be used with extreme caution in patients with cardiac involvement due to risk of worsening heart failure and fluid retention. It is not a routine first- or second-line agent for cardiac AL amyloidosis.

Before the proteasome inhibitor era, oral melphalan plus prednisolone (MP) and melphalan plus dexamethasone (MDex) were primary treatments, with median OS of 12-24 months for cardiac-involved patients. These have been entirely superseded by bortezomib-based and now daratumumab-based regimens and should not be used as frontline therapy except in extraordinary circumstances under specialist guidance.

Doxycycline and TUDCA (tauroursodeoxycholic acid) were investigated as possible fibril-destabilizing agents based on laboratory evidence. No prospective randomized trial has demonstrated clinical benefit for doxycycline in AL amyloidosis. Not used at major amyloidosis centers. Should not be started without specialist guidance. (Note: doxycycline is used in Val30Met hereditary ATTR amyloidosis — a different disease.)

AL amyloidosis is rare enough that even excellent oncologists and cardiologists may see fewer than 2–3 cases per year. The difference in outcomes between patients treated at specialized amyloidosis centers versus community hospitals is substantial, driven by experience with AL-specific cardiac management, access to investigational protocols, and institutional familiarity with the nuances of response assessment. Understanding how to navigate this system empowers you to get the best possible care.

Getting the right initial diagnosis: AL amyloidosis is frequently diagnosed late — the average time from first symptom to diagnosis is 2–3 years, and patients often see 4–5 physicians before a diagnosis is made. Common misdiagnoses include congestive heart failure of unknown origin, idiopathic nephrotic syndrome, MGUS with unexplained symptoms, and polyneuropathy. If you have one of these diagnoses along with another organ involvement that seems unexplained, ask your physician whether amyloidosis testing has been done (fat pad biopsy, urine protein electrophoresis, serum free light chains). These tests are inexpensive and minimally invasive — there is no reason to delay them.

When to go to a specialized amyloidosis center:

At diagnosis — at least for a second opinion and initial staging. The treatment plan set in the first weeks determines outcomes for years.
If your initial physician has not done fat pad biopsy or amyloid subtyping by mass spectrometry
Before any decision about stem cell transplant eligibility or refusal
If you are not achieving hematologic response after 2–3 cycles
If you relapse after initial treatment
For complex cardiac or renal management that exceeds local expertise

Questions to ask when choosing a center:

How many new AL amyloidosis patients does your program treat per year?
Do you have a dedicated cardiac amyloidosis program with cardiologists experienced in AL specifically?
Do you perform high-dose melphalan + autologous stem cell transplant for AL amyloidosis (not just myeloma)?
Do you have access to amyloid subtyping by mass spectrometry on-site, or do you send samples to Mayo/Boston University?
Are you currently enrolling patients in AL amyloidosis clinical trials?
Can I continue primary care locally and consult with you for major decisions?

How to request a second opinion: Most amyloidosis centers accept direct patient-initiated consultation requests. Contact the center’s amyloidosis clinic directly (not just the main hospital line) with your diagnosis and your pathology/biopsy reports. Most centers require: the biopsy report with Congo red staining results and subtyping method; serum protein electrophoresis and immunofixation; serum free light chain results; 24-hour urine results; echocardiogram report; cardiac biomarkers (NT-proBNP and troponin). Many centers offer telemedicine consultations, which are particularly valuable for patients in regions far from major centers. Insurance usually covers specialist consultations; verify before booking. The Amyloidosis Support Groups (amyloidosis.org) maintains a list of specialized US and international centers and can assist with navigation and referral questions.

Coordinating care between your local team and a specialist center: Many AL patients successfully maintain primary chemotherapy administration locally (for convenience and cost) while consulting with a specialized center for staging, treatment planning, and management of complications. For this to work: ensure records flow promptly in both directions; specify clearly who is the "captain of the ship" for treatment decisions; ensure your local cardiologist and the specialist cardiologist communicate directly if cardiac management is complex. This hybrid model is explicitly supported by major AL programs and is the norm for patients located more than 2–3 hours from a center.

class="content-section" data-stage="all">

Specialist Centers and Referral Directory

AL amyloidosis requires subspecialty expertise that most general oncologists and hematologists do not have. Amyloid typing by mass spectrometry, Mayo staging, organ response assessment, ASCT eligibility evaluation, and trial enrollment all require centers with dedicated amyloidosis programs.

University of Utah Health — Huntsman Cancer Institute
Hematology/Oncology Division — Plasma Cell Disorders Program
Phone: 801-581-2121
Services: Diagnostic workup, bortezomib-based chemotherapy, referral to HCI BMT for ASCT evaluation, bone marrow biopsy with FISH, clinical trial access

Huntsman Cancer Institute — Blood and Marrow Transplant (BMT) Program
Phone: 801-585-0303
Services: ASCT eligibility evaluation and transplant for eligible AL amyloidosis patients; pre-transplant cardiac and renal clearance

George E. Wahlen VA Medical Center — Salt Lake City
Phone: 801-582-1565
VA Community Care: 1-877-881-7618. Veterans eligible for community care referrals to Stanford, Mayo, or Columbia under the MISSION Act when local VA resources are insufficient.

Stanford Amyloid Center — Stanford University Medical Center
Lead Physician: Ronald Witteles, MD (cardiologist specializing in cardiac amyloidosis)
Phone: 650-723-6649
~750 miles from Salt Lake City. Strengths: cardiac amyloidosis expertise, integrated cardiology-hematology program, cardiac MRI, ASCT, active clinical trials.

Boston University Amyloidosis Center — Boston Medical Center
Lead Physician: John L. Berk, MD
Phone: 617-638-4317
~2,100 miles from Salt Lake City. One of the largest dedicated amyloidosis programs in the world; full typing and staging; active trials; ARC-affiliated registry center.

Mayo Clinic — Rochester, Minnesota
Lead Physician: Morie A. Gertz, MD
Phone: 507-538-3270
~1,400 miles from Salt Lake City. Co-developer of Mayo staging system; mass spectrometry typing; ASCT; largest US AL amyloidosis registry.

Stanford University — Stanford Cancer Institute
Lead Physician: Surbhi Sidana, MD (leads the myeloma/amyloidosis CAR-T & immunotherapy program)
Phone: 650-498-6000
Active clinical trials including CAR-T and venetoclax studies; ASCT program.

MD Anderson Cancer Center — Houston, Texas
Phone: 877-632-6789
Plasma cell disorder program with amyloidosis expertise; Phase 1/2 trial access; closest major center for Utah patients traveling to Texas.

VA Community Care Program
Phone: 1-877-881-7618
Veterans with AL amyloidosis who need subspecialty amyloidosis care unavailable at their local VAMC are entitled to community care referrals under the MISSION Act. Request referral to the nearest amyloidosis center of excellence. The VA Caregiver Support Line is 1-855-260-3274. Daratumumab is on the VA national formulary; authorization processes vary by VISN.

Princess Margaret Cancer Centre — Toronto, Ontario
Lead Physician: Dr. Suzanne Trudel
Phone: 416-946-4501
Canada's leading plasma cell disorder and amyloidosis program; active trial enrollment; ASCT; FISH and mass spectrometry typing available.

Ottawa Hospital Blood and Marrow Transplant Program
Phone: 613-737-8899

UCL National Amyloidosis Centre — Royal Free Hospital, London, UK
Lead Physician: Prof. Philip Hawkins
Phone: +44 20 7794 0500
One of the world's largest amyloidosis programs; provides typing, staging, and treatment for all UK patients and international referrals.

Heidelberg University Hospital — Germany
Lead Physician: Prof. Stefan Schönland
Germany's national amyloidosis center; mass spectrometry typing, integrated cardiology-haematology clinic, European trial access.

Amyloidosis Research and Treatment Center — Pavia, Italy
Lead Physician: Prof. Giovanni Palladini
Fondazione IRCCS Policlinico San Matteo, University of Pavia. Co-developed Mayo staging and IWG criteria; one of the largest global cohort databases.

Living With AL Amyloidosis — Daily Life, Support, and Planning

AL amyloidosis changes daily life in profound ways. Treatment is demanding. Cardiac and renal involvement requires active self-management alongside medical therapy.

Cardiac Precautions and Daily Monitoring

Daily Weight and Fluid Monitoring — Critical Habit
Weigh yourself every morning before eating, after using the bathroom, wearing similar clothing. Record the number. Contact your care team if you gain more than 2 pounds in 24 hours or 5 pounds in a week.

Sodium restriction: Limit dietary sodium to 2 grams (2,000 mg) per day. Read food labels carefully — canned soups, deli meats, restaurant food, and condiments are hidden sodium sources.
Fluid restriction: If cardiac involvement with significant heart failure, limit total fluid intake to 1.5 liters (~50 oz) per day as directed by your team.
AVOID digoxin: Amyloid fibrils bind digoxin and cause toxicity even at standard doses. If any provider prescribes digoxin, remind them of your AL amyloidosis diagnosis immediately.
Verapamil and diltiazem: absolutely contraindicated. Do not take these under any circumstances.
Activity: Light activity (short walks, gentle stretching) is encouraged. Rest when fatigued — fatigue in AL amyloidosis reflects low cardiac output, not laziness.

Peripheral Neuropathy — Foot Care and Fall Prevention

Inspect feet daily for cuts, blisters, or sores — reduced sensation means you may not feel injuries
Wear well-fitted, supportive footwear at all times; avoid walking barefoot
Remove fall hazards: loose rugs, electrical cords, poor stair lighting
Install grab bars in the bathroom; use a shower chair if balance is compromised
Ask for a physical therapy referral for gait and balance training

Immunocompromised Precautions

Antiviral prophylaxis (acyclovir or valacyclovir) is standard during bortezomib therapy to prevent herpes zoster reactivation
Daratumumab causes positive Coombs test — inform blood bank before any procedures requiring crossmatch
COVID-19, influenza, and pneumococcal vaccines recommended (timing relative to therapy as directed)
Avoid live vaccines during active treatment
Call care team immediately for fever over 100.4°F (38°C) — do not wait for scheduled appointment

Financial Toxicity and Assistance Programs

Janssen CarePath — Daratumumab Co-Pay Assistance
Phone: 1-800-652-6227 | janssencarepath.com/patient/darzalex

Leukemia & Lymphoma Society (LLS) Co-Pay Assistance
Phone: 1-877-557-2672 | lls.org/support-resources/financial-support

LLS Patient Information Specialists
Phone: 1-800-955-4572

NeedyMeds: needymeds.org — database of patient assistance programs by drug name

Mental Health

An AL amyloidosis diagnosis is a medical crisis. Ask your care team for a referral to oncology social work or palliative care psychology. If you feel unable to cope or are having thoughts of self-harm, call the 988 Suicide and Crisis Lifeline (call or text 988) immediately. Peer support through the Amyloidosis Foundation (1-877-426-9524) can reduce isolation.

Advance Care Planning

POLST (Physician Orders for Life-Sustaining Treatment): A legal medical order specifying your wishes regarding CPR, mechanical ventilation, and hospitalization. Appropriate for patients with serious illness and organ compromise. Ask your care team or social worker to help you complete one.

Healthcare proxy / durable power of attorney: Designate someone who can make medical decisions on your behalf if you cannot.

Palliative care: Symptom management alongside curative treatment should be integrated from early in the disease course. Ask your care team how to access this.

What is my specific target weight for daily monitoring, and at what weight change should I call your office?
What is my exact sodium and fluid limit per day?
What medications on my current list should I stop or avoid?
Is it safe for me to exercise? What type and how much?
Can you refer me to a palliative care specialist for symptom management alongside my treatment?
Is there an oncology social worker I can speak with about financial assistance and emotional support?
What should I tell my other doctors (cardiologist, nephrologist, primary care) about my AL amyloidosis diagnosis and the medications I must avoid?
When should we start talking about advance directives and goals of care?

AL amyloidosis with cardiac and/or kidney involvement creates a unique management challenge: both organs compete for fluid management. The kidneys leak protein and lose fluid-regulating ability; the heart cannot handle excess volume. Navigating this balance is one of the most practical day-to-day challenges for AL patients and their families.

Fluid and sodium restriction (cardiac AL): Most AL patients with cardiac involvement are placed on a fluid intake limit of 1.5–2 liters per day and a sodium restriction of <2 grams/day. This is not a guideline; it is usually individualized by your cardiologist based on your current clinical status. Weigh yourself every morning before eating and after urinating. A weight gain of >2–3 pounds in a day, or >5 pounds in a week, signals fluid retention that requires a call to your cardiologist — diuretic adjustment is often needed before fluid backup causes respiratory distress.

Diuretics in AL: Loop diuretics (furosemide, torsemide, bumetanide) are the mainstay of fluid management in cardiac AL. Torsemide is often preferred over furosemide due to more reliable oral bioavailability (intestinal edema in AL can impair furosemide absorption). You may need higher doses than in ordinary heart failure due to AL-related kidney impairment. Aldosterone antagonists (spironolactone) are often added for additional diuresis but must be used cautiously given the risk of hyperkalemia in patients with CKD. Monitor your electrolytes (potassium, sodium) weekly when doses are being adjusted. Report symptoms of low potassium: muscle cramps, leg weakness, palpitations.

Orthostatic hypotension (autonomic AL): For patients with autonomic neuropathy, standing up quickly causes a sudden drop in blood pressure that can cause dizziness, lightheadedness, or fainting. Management: rise slowly from lying to sitting before standing; use compression stockings; sleep with the head of the bed elevated 10–20°; eat small frequent meals rather than large meals; stay well-hydrated within your fluid limit. Midodrine or fludrocortisone are sometimes prescribed for severe cases, but both can worsen heart failure. The management of autonomic neuropathy and cardiac AL simultaneously is genuinely difficult and benefits from a specialized AL program.

Exercise: Moderate activity as tolerated is appropriate for most AL patients in stable, treated disease. Cardiac AL-specific restrictions: avoid isometric exercises (heavy lifting), avoid activities requiring prolonged Valsalva (straining), monitor for new dyspnea or palpitations with any new exercise intensity. A cardiac rehabilitation program designed for restrictive cardiomyopathy can be beneficial once the plasma cell disease is under treatment control.

Fertility Preservation & Pregnancy with AL Amyloidosis

AL amyloidosis can affect people in their 30s and 40s. Most treatments are harmful to a developing baby, so fertility preservation and contraception planning are essential before starting any therapy.

Fertility preservation before treatment

Many AL amyloidosis treatments damage eggs and sperm. If you are of reproductive age and newly diagnosed, ask about urgent fertility preservation (egg/embryo freezing for women, sperm banking for men) before treatment begins. A reproductive endocrinologist can usually arrange this within a few days.

Treatment medications and pregnancy

Most AL amyloidosis treatments must not be used during pregnancy. Speak with your hematologist before becoming pregnant.

Thalidomide and lenalidomide (Revlimid) — severely teratogenic. These drugs cause major birth defects (thalidomide) and are Category X. They are dispensed only through a strict REMS program that requires monthly pregnancy tests and effective contraception for all patients (women and male partners). Never take these during pregnancy.
Bortezomib (Velcade) — limited pregnancy data; animal studies show harm. Avoid during pregnancy. Effective contraception required.
Daratumumab (Darzalex) — may cause fetal harm; avoid during pregnancy. Effective contraception required.
Melphalan (used in stem cell transplant) — severely toxic to eggs and sperm (alkylating agent). May cause premature menopause. Avoid in pregnancy. Stem cell transplant is not performed during pregnancy.
Dexamethasone — corticosteroids can be used during pregnancy in limited circumstances; discuss the balance of risks with your specialist.

Pregnancy and organ involvement

If AL amyloidosis has affected your kidneys or heart, pregnancy carries additional risks. Kidney disease from amyloidosis increases the risk of preeclampsia and preterm birth. Cardiac amyloidosis significantly increases maternal risk during pregnancy. These issues must be fully discussed with your hematologist, cardiologist, nephrologist, and maternal-fetal medicine specialist before any pregnancy attempt.

Bottom line: fertility preservation before treatment and effective contraception during treatment are essential. If your disease is well controlled and organ function is stable, a future pregnancy may be possible — discuss your individual situation with your care team.

AL amyloidosis is a rare disease, which means patients often encounter treatments promoted in online communities, alternative medicine contexts, or from well-meaning acquaintances that have not been rigorously tested. Knowing how to evaluate these claims — and how to find legitimate clinical trials — protects you from harm and opens doors to potentially beneficial emerging treatments.

Evaluating treatment claims: questions to ask

Has it been tested in AL amyloidosis specifically, or just in myeloma or "blood cancers" generally? AL amyloidosis has fundamentally different biology and toxicity profiles from myeloma. A treatment showing benefit in myeloma may cause harm in AL. Ask for AL-specific data, not just plasma cell disorder data.
What was the study design? Case reports and case series (1–30 patients) generate hypotheses, they do not establish efficacy. Randomized controlled trials (RCTs) establish causation. Phase 3 RCTs with organ and survival endpoints are the gold standard in AL. Ask: was this a randomized trial? How many patients? Were they similar to your case?
Who funded the study? Manufacturer-sponsored trials are the norm in drug development and are not inherently biased, but understanding who is behind the data helps you evaluate it contextually. Non-profit and academic investigator-initiated trials often provide the most independent data.
Has it been peer-reviewed and published in a reputable journal? The New England Journal of Medicine, Blood, Journal of Clinical Oncology, Amyloid, and Leukemia are high-quality journals for AL amyloidosis data. Social media posts, company websites, and patient testimonials are not peer review.
What are the risks, not just the benefits? Every potentially effective treatment has potential harms. In AL amyloidosis specifically, cardiac, renal, and autonomic toxicities can be severe and life-threatening. A treatment that "showed benefit" in a case series with no mention of toxicity should be viewed with skepticism.

Treatments to be especially cautious about:

High-dose IV vitamin C: No evidence of efficacy in AL amyloidosis. Can cause oxalate nephropathy in susceptible patients. Interferes with 24-hour urine M-protein and proteinuria measurements — can falsely inflate values and trigger unnecessary treatment changes.
Herbal immunosuppressants (astragalus, mistletoe/Iscador, cat's claw, etc.): Many herbal immunomodulators interact with CYP enzymes and P-glycoprotein, affecting blood levels of bortezomib, lenalidomide, and daratumumab. Some activate immune pathways that theoretically could worsen plasma cell disease or increase organ inflammation. Always disclose every supplement to your AL team before taking it.
"Amyloid-dissolving" supplements: Various supplements (EGCG, curcumin, resveratrol) have been marketed as dissolving amyloid deposits based on laboratory data. There is no evidence these dissolve established amyloid in humans at supplement doses, and as noted above, EGCG directly inhibits bortezomib’s mechanism of action. Do not take without discussion with your amyloidosis specialist.
Unproven infusion therapies at alternative clinics: High-dose nutrient infusions, ozone therapy, and similar treatments are offered commercially for many conditions. None has evidence in AL. Some carry direct risks in patients with cardiac AL (volume loading, infection in immunocompromised patients). Decline until you have discussed with your AL team.

Clinical trials in AL amyloidosis: why they matter and how to find them

Clinical trials are not a "last resort" for AL amyloidosis patients — they are frequently the best available option, especially for patients who have relapsed or who are in parts of the world where approved therapies are less accessible. Participation also advances the science for future patients with this rare disease.

How to find AL amyloidosis trials:

ClinicalTrials.gov: The official US registry. Search for "AL amyloidosis" or "light chain amyloidosis" under condition, and filter by status "Recruiting." Review eligibility criteria carefully — most trials require specific prior treatment history, organ function thresholds, and geographic access to trial sites.
EU Clinical Trials Register (clinicaltrialsregister.eu): For European trial access.
Your amyloidosis center: Major AL amyloidosis centers (Boston University, Stanford, Mayo Clinic, Indiana University, UK National Amyloidosis Centre) often run investigator-initiated trials not prominently listed in databases. Direct inquiry is essential.
Patient advocacy organizations: The Amyloidosis Research Consortium (arc4cure.org), the Amyloidosis Support Groups (amyloidosis.org), and the Amyloidosis Foundation maintain trial listings and patient navigators who can assist with matching and transportation logistics.

When inquiring about a trial, ask your current hematologist first — some trials allow continuation of standard care alongside the experimental treatment, and your hematologist may need to coordinate referral. If your hematologist is not familiar with AL trials, ask for a consultation with a specialist AL center even if you continue primary care locally.

Glossary of Key Terms

Amyloid: A protein that has misfolded and aggregated into abnormal fibril structures that deposit in organs and tissues. Many different proteins can form amyloid; the type is determined by the source protein.
AL Amyloidosis (Light Chain Amyloidosis): The most common form of systemic amyloidosis in Western countries. Caused by a plasma cell clone in the bone marrow that produces abnormal immunoglobulin light chains that misfold into amyloid fibrils depositing in organs (especially heart, kidneys, nerves, liver, GI tract).
ASCT (Autologous Stem Cell Transplant): A procedure in which a patient's own blood stem cells are collected, then high-dose chemotherapy (melphalan) destroys the plasma cell clone, and the stem cells are infused back to restore bone marrow function. Only approximately 20% of AL amyloidosis patients are eligible.
ATTR (Transthyretin Amyloidosis): A different type of amyloidosis caused by misfolding of transthyretin (TTR) protein — either due to inherited mutations (hereditary ATTR) or aging (wild-type ATTR). Treated with completely different drugs than AL amyloidosis (tafamidis, patisiran, vutrisiran). ATTR treatments do not help AL amyloidosis.

BCL-2: An anti-apoptotic protein that prevents cells from undergoing programmed cell death. Plasma cells with the t(11;14) translocation are highly dependent on BCL-2 for survival, making them specifically vulnerable to venetoclax (a BCL-2 inhibitor).
Bortezomib (Velcade): A proteasome inhibitor that blocks the cellular machinery plasma cells use to manage protein waste. Disrupts plasma cell ability to produce abnormal light chains and induces cell death. One of the three drugs in CyBorD. Given by subcutaneous injection.
Congo Red Stain: The standard histological stain used to identify amyloid deposits in biopsy tissue. Amyloid stained with Congo red shows characteristic apple-green birefringence under polarized light microscopy — the diagnostic hallmark of amyloidosis. A positive Congo red stain confirms amyloid is present but does NOT identify the type.
CR (Complete Hematologic Response): The deepest level of hematologic response — no detectable abnormal light chains in blood or urine, normal free light chain ratio, and no bone marrow plasma cells detectable. CR is associated with the best long-term outcomes.
CyBorD: Cyclophosphamide + Bortezomib + Dexamethasone. The standard chemotherapy backbone of frontline AL amyloidosis therapy, used alone or with daratumumab (Dara-CyBorD).

Dara-CyBorD: The current FDA-approved standard of care for newly diagnosed AL amyloidosis: Daratumumab (subcutaneous) + Cyclophosphamide + Bortezomib + Dexamethasone. Full approval November 2025.
Daratumumab (DARZALEX FASPRO): An anti-CD38 monoclonal antibody (Janssen) that targets and destroys plasma cells. Given as a subcutaneous injection (3-5 minutes) co-formulated with hyaluronidase.
dFLC (Difference in Free Light Chains): The difference between the involved (abnormal) and uninvolved (normal) free light chain levels in blood. Used in Mayo 2012 staging (threshold 180 mg/L) and to monitor treatment response. A falling dFLC indicates the plasma cell clone is responding to therapy.

FISH (Fluorescence In Situ Hybridization): A laboratory technique that detects specific chromosomal abnormalities in plasma cells from bone marrow biopsy. The most important FISH finding in AL amyloidosis is t(11;14) — present in ~45% of patients and predicts exceptional response to venetoclax.
Free Light Chains (FLC): Immunoglobulin light chains (kappa and lambda) that circulate freely in the blood. In AL amyloidosis, the plasma cell clone overproduces one type, creating an imbalanced ratio. Monitored throughout treatment by the Freelite assay to track response.

Macroglossia: Enlargement of the tongue due to amyloid infiltration. Present in approximately 10-15% of AL patients — one of the most visible and specific signs. Can cause difficulty swallowing, speaking, and sleeping.
Mass Spectrometry (LMD/MS): The gold standard laboratory method for typing amyloid fibrils in biopsy tissue. Laser capture microdissection cuts Congo red-positive areas from the tissue slide; mass spectrometry identifies the exact protein composition of the fibril, definitively distinguishing AL from ATTR, AA, and other rare forms. Do not accept treatment without mass spectrometry-confirmed typing.
Mayo 2012 Staging System: The most widely used staging system for AL amyloidosis, based on three biomarkers: cardiac troponin T (TnT ≥0.025 ng/mL), NT-proBNP (≥1,800 pg/mL), and dFLC (≥180 mg/L). Each abnormal value adds one point. Stages I (0 points) through IIIb (all three abnormal, NT-proBNP ≥8,500 pg/mL).

NT-proBNP (N-terminal pro-B-type Natriuretic Peptide): A cardiac biomarker released under stress or damage. Markedly elevated in AL cardiac amyloidosis. Used in Mayo 2012 staging (threshold 1,800 pg/mL) and to monitor cardiac response. Falling NT-proBNP ≥30% from baseline indicates cardiac organ response.
Organ Response: Improvement in the function of an organ damaged by amyloid deposits. Typically lags hematologic response by 6-18 months as amyloid deposits gradually resorb once new fibril production stops. Defined criteria exist for cardiac, renal, liver, and nerve organ responses.

t(11;14) Translocation: A chromosomal abnormality (swap of genetic material between chromosomes 11 and 14) found in approximately 45% of AL amyloidosis patients. Detected by FISH on bone marrow biopsy. Predicts exceptional response to venetoclax. All newly diagnosed AL amyloidosis patients should have FISH performed at diagnosis to determine t(11;14) status.
VGPR (Very Good Partial Response): A hematologic response level in which dFLC falls to less than 40 mg/L. VGPR or better is the minimum response target in modern AL amyloidosis therapy. CR is the goal; VGPR is the floor of acceptability.
Venetoclax (Venclexta): A BCL-2 inhibitor (AbbVie) FDA-approved for CLL and AML but not yet specifically for AL amyloidosis. Highly effective in t(11;14)-positive patients. Used off-label at specialized centers or within clinical trials (e.g., NCT04847453).

Achieving complete hematologic response (CR) in AL amyloidosis does not mean the monitoring stops. Long-term surveillance serves three critical purposes: (1) detecting hematologic relapse early, before organ damage re-accumulates; (2) monitoring organ recovery and the slow clearance of amyloid deposits; and (3) managing the long-term consequences of both the disease and its treatment.

Hematologic surveillance (checking whether the plasma cell clone has returned):

Serum free light chains (SFLC) and dFLC: The most sensitive tool for detecting residual or recurrent plasma cell disease. Measured every 3 months in remission for the first 2 years, then every 6 months if stable.
Serum and urine immunofixation (SPEP/UPEP with IFE): Detects M-protein in blood and urine. Monthly in the first year after transplant; quarterly thereafter.
Bone marrow biopsy: Done after transplant to confirm CR; repeated if SFLC suggests relapse or if there is unexplained worsening of organ function.
Minimal residual disease (MRD) testing: Next-generation flow cytometry (NGF) or next-generation sequencing (NGS) can detect residual plasma cells at 1 in 10,000 to 1 in 1,000,000 — below the detection threshold of standard immunofixation. MRD negativity predicts the best long-term outcomes. MRD testing in AL is increasingly used at specialized centers and in clinical trials but is not yet standard at all programs.

Cardiac surveillance:

NT-proBNP and troponin T: every 3 months for 2 years; then every 6 months. A new rise in NT-proBNP is the earliest warning of either hematologic relapse or progressive cardiac amyloid, and requires rapid evaluation.
Echocardiogram: every 6–12 months to track structural cardiac changes (wall thickness, diastolic function, GLS). Improvement in GLS is one of the most sensitive indicators of cardiac organ response.
Holter monitoring or ambulatory ECG: Annually in patients with known arrhythmia history or in those with significant wall thickening, to check for subclinical atrial fibrillation or AV block development.

Renal surveillance:

24-hour urine protein quantification: every 3–6 months to track proteinuria trajectory. A plateau or re-rise after initial improvement requires evaluation for relapse.
eGFR: every 3 months. Decline in eGFR despite maintained hematologic response may reflect continued amyloid-driven glomerular damage or medication toxicity (especially with bisphosphonates or NSAIDs).
Nephrology co-management: patients with eGFR <45 or on dialysis should have nephrology formally co-managing their care, coordinating around transplant eligibility if kidneys worsen despite treatment.

Long-term treatment consequences to monitor:

Peripheral neuropathy (from bortezomib or pre-existing AL neuropathy): Formal neurology evaluation at baseline and at 6–12 month intervals. Physical therapy and occupational therapy referrals for fall prevention and functional preservation if neuropathy is progressing.
Secondary malignancies after HDM-ASCT: Slightly elevated lifetime risk of myelodysplastic syndrome (MDS) and AML years after high-dose alkylating agent therapy. No specific screening test prevents this, but CBC abnormalities warrant prompt bone marrow evaluation.
Bone health (from chronic corticosteroids and/or bisphosphonates): DEXA scan at baseline; repeat every 2 years. Vitamin D and calcium supplementation guided by lab values and serum calcium.
Hypogammaglobulinemia: Prolonged suppression of normal plasma cells from daratumumab and prior chemotherapy often results in low IgG levels, increasing infection risk. Check IgG periodically; consider IVIG replacement if recurrent serious bacterial infections occur in the context of IgG <400 mg/dL.

When to call your team immediately during surveillance:

New or worsening edema (legs, abdomen, or facial) between scheduled appointments
Weight gain >3 pounds in 24 hours
New shortness of breath, particularly at rest or when lying flat
Any palpitations lasting >30 seconds, or syncope/near-syncope
Significant drop in urine output over 24–48 hours
Fever >101°F — immunocompromised patients can deteriorate rapidly with infections

Resources, Support Organizations, and Key References

Patient and Caregiver Organizations

Amyloidosis Research Consortium (ARC)
Website: arci.org
The leading nonprofit funding AL amyloidosis research and supporting patients. Maintains a patient registry, clinical trial navigator, and patient education resources.

Amyloidosis Foundation
Phone: 1-877-426-9524
Website: amyloidosis.org
Patient education, caregiver support, peer patient support network, and annual patient/family conference.

Leukemia & Lymphoma Society (LLS)
Phone: 1-800-955-4572
Website: lls.org
Free information specialists, financial assistance, and peer support programs. Co-pay assistance: 1-877-557-2672.

NORD (National Organization for Rare Disorders)
Website: rarediseases.org
Disease overview, patient assistance program database, and rare disease advocacy resources.

Financial Assistance

Janssen CarePath (Darzalex Faspro): 1-800-652-6227 — co-pay assistance; prior authorization support
LLS Co-Pay Assistance: 1-877-557-2672
Patient Advocate Foundation Co-Pay Relief: copays.org
NeedyMeds: needymeds.org — database of patient assistance programs by drug name

Clinical Trial Resources

ClinicalTrials.gov: clinicaltrials.gov — Search "AL amyloidosis" + Recruiting for currently enrolling trials
ARC Trial Navigator: arci.org

Key Scientific References

Based on:

Kastritis E, et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis (ANDROMEDA). N Engl J Med 2021;385:46-58. PMID 34192431
Kumar S, et al. Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements (Mayo 2012). J Clin Oncol 2012;30:989-995. PMID 22331953
Palladini G, et al. New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis. J Clin Oncol 2012;30:4541-4549. PMID 23091105
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Systemic Light Chain Amyloidosis. Version 2.2026. Available at nccn.org
Dispenzieri A, et al. Treatment of immunoglobulin light chain amyloidosis: Mayo mSMART Consensus Statement. Mayo Clin Proc 2015;90:1054-1081
Muchtar E, et al. How I treat AL amyloidosis. Blood 2021;137:2585-2596
NICE Technology Appraisal TA959. Daratumumab with bortezomib, cyclophosphamide and dexamethasone for treating newly diagnosed systemic AL amyloidosis. 27 March 2024. nice.org.uk/guidance/ta959

Disclaimer: This guide provides educational information only. It is not a substitute for professional medical advice, diagnosis, or treatment. AL amyloidosis is a complex, rapidly evolving field — treatment decisions must be made with a physician who specializes in plasma cell disorders and amyloidosis. Always seek care at or in consultation with a dedicated amyloidosis center.

What This Guide Does Not Know

This guide cannot diagnose or treat. AL amyloidosis requires an expert multidisciplinary team.
Field moving fast. Venetoclax for t(11;14), isatuximab, next-generation BCMA antibodies, CAR-T cells — these are in active trials and the evidence base is changing rapidly. This guide reflects the state of the field as of May 2026.
Seek expert consultation. Referral to an amyloidosis center improves outcomes. A second opinion is appropriate for all newly diagnosed patients.

A final word. AL amyloidosis is urgent but increasingly treatable. Daratumumab has transformed outcomes. Get correct amyloid typing by mass spectrometry. Get to an experienced team quickly. Ask about the t(11;14) translocation and venetoclax. Ask about clinical trials. You are not alone — the Amyloidosis Research Consortium (arci.org) and Amyloidosis Foundation (1-877-426-9524) exist to help patients and families navigate exactly this situation.